Compositions containing cannabinoid analog conjugates and methods of use

ABSTRACT

Embodiments of the disclosure provide a method of man-aging information related to a cannabis product across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of the cannabis product, and measurements of quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing the cannabis product to determine the quality and quantity of desired components and undesired components in the cannabis product. The method includes determining concentration of cannabinoids in the cannabis product.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/291,943, filed Mar. 4, 2019, title “Systems and Methods for Integrated and Comprehensive Management of Cannabis Products,” which is a continuation-in-part application of U.S. patent application Ser. No. 15/470,562, filed on Mar. 27, 2017, titled “Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes,” which is a continuation application of U.S. patent application Ser. No. 14/312,051, filed on Jun. 23, 2014, now issued as U.S. Pat. No. 9,632,069, titled “Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes,” which claims the benefit of and priority to U.S. Provisional Patent Application No. 61/936,200, filed on Feb. 5, 2014, titled “Systems and Methods of Evaluating Cannabis Products for Public Safety, Quality Control and Quality Assurance Purposes;” and U.S. Provisional Patent Application No. 61/939,385, filed on Feb. 13, 2014, titled “Systems and Methods of Evaluating Cannabis Products for Public Safety, Quality Control and Quality Assurance Purposes,” the disclosures of which are each hereby incorporated by reference in their entireties. This application is also a continuation-in-part application under 35 U.S.C. § 111(a) of the PCT application No. PCT/US2018/42707, filed on Jul. 18, 2018, titled “Compositions Containing Cannabinoid Analog Conjugates and Methods of Use,” which claims the benefit of and priority to U.S. Provisional Patent Application No. 62/533,894, filed on Jul. 18, 2017, titled “Compositions Containing Cannabinoid Analog Conjugates and Methods of Use,” the disclosures of which are each hereby incorporated by reference in their entireties.

TECHNICAL FIELD

Embodiments of the disclosure relate generally to the field of managing information about natural products such as cannabis and cannabinoid products for quality control and quality assurance purposes. More specifically, embodiments of the present disclosure facilitate a supplier or a consumer of a cannabis and/or cannabinoid product to evaluate the efficacy, potency, quality and origin of such product. Embodiments of the disclosure also relate to a cannabis and cannabinoid processing center where samples of such products are analyzed for public safety, quality control, and quality assurance purposes. Embodiments of disclosure also relate to testing and tracking medicinal products, such as cannabis and cannabis products, for evaluation by healthcare professionals and patients for quality control, quality assurance, and therapeutic efficacy.

This disclosure relates to synthetic cannabinoid compositions and methods generally directed to using such compositions for diagnostic, therapeutic, and prognostic applications.

BACKGROUND

Cannabis and cannabinoid products are legally available for human consumption for several purposes, including, but not limited to, medicinal, research and recreational purposes. Undesired and in some cases toxic chemicals, including pesticides and plant growth regulators, tag along with the cannabis products and threaten the health of the consumers. As some cannabis products can be inhaled rather than eaten, any toxins carried by the products have a direct route into the lungs and blood stream of the consumer. Some states have regulations for controlling the environment where the cannabis plants are grown. Most states where cannabis products can be legally obtained, have no means for ensuring that the plants are grown under controlled environments. In addition to natural contamination during growth of the plants, cannabis and cannabinoid products are unscrupulously contaminated by using extracts or dried parts of other plants, glass particles, industrial chemicals, sugar or sand, and other micro contaminants. There are no robust integrated systems to ensure that the cannabis and cannabinoid products are free of chemical and microbiological contamination, and that the product can be traced as the plant is grown, processed into products, and moved to stores for public consumption. Most consumers do not have access to cannabis or cannabinoid products that have been tested for purity by third party validated labs.

Medical cannabinoids and botanical drugs have emerged as a viable means of therapy with growing scientific evidence of therapeutic potential. However, very little work has been done for assuring safe cannabis product development and consumption, and evaluating the direct correlation to disease outcomes. Various methods of hybridization of the cannabis seed has been employed to exploit the variance in cannabinoid profile produced by the plant. However, cannabis product characterization and its connection to disease outcomes have yet to be tracked with precision. Variations in methodology can lead to inconsistency in cannabinoid product formation as well as generating other uncertainties in the progeny that cannot be initially predicted, such as increase in terpene production. Without a comprehensive verification/validation process, distortion in medical prognosis and diagnosis of providing recommendation or prescribing cannabis for various disease states can arise. Furthermore, public safety and public trust are the thrusts behind policy and regulation surrounding medical cannabis. Current platforms lack a comprehensive approach to management of the various aspects of the industry, such as selection of the cannabis seed genetics, managing plant growth conditions, production of products and medicaments with directed safety and therapeutic profiles.

Medical cannabinoids have not been well developed for theranostic applications. Strategic clinical trials still lag behind, due to public stigmatization and law-imposed criminalization. However, petitions for therapeutic application of medical cannabinoids from healthcare providers, patients and activist advocates have exponentially increased. The cannabinoid receptors (CBi and CB₂), transient receptor potential subfamily V member 1 (TRPV1), transient receptor potential subfamily A member 1 (TRPA1), and the orphan receptor GPR55 are part of the endocannabinoid system (ECS), which is a complex lipid signaling network involving different proteins for the control or modulation of numerous physiological and pathophysiological processes. Along with these receptors, the ECS includes arachidonic acid-derived ligands, anandamide and 2-arachidonoyl glycerol, and the enzymes that degrade these endocannabinoids, such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). While the expression of the CBi receptor is ubiquitous, with predominant presence in the brain, particularly in the basal ganglia, hippocampus, cerebellum and cortex, the CB₂ receptor is preferentially located in tissues that comprise the immune system (especially within the B cell rich compartments). Consistent with its broad distribution, CBi can be similarly detected in peripheral nerves and beyond the neural compartments, i.e., testis, uterus, vascular endothelium, eye, spleen, ileum and adipocytes. Because CBi and CB₂ receptors share 68% amino acid sequence identity at the trans-membrane domain, cannabinoid ligand/receptor pathways are being consistently evaluated as rational therapeutic targets for neurodegeneration in Alzheimer's, Parkinson's, Huntington's diseases; indolent pain, which is common in glaucoma and multiple sclerosis; and diverse cardiovascular disorders; and cancer.

SUMMARY

Applicants recognize the public health and safety risks that exist when cannabis or cannabinoid products are not accompanied by adequate information about their sources, manufacturing practices, contents, results of any quality testing and quality assurance procedures. Undesired and in some cases toxic chemicals, including pesticides and plant growth regulators, tag along with cannabis and cannabinoid products and threaten the health and safety of the consumers, so additional testing and compliance activities may be needed before public consumption. Embodiments of the disclosure include, for example, a cannabis processing center where samples of cannabis and cannabinoid products are analyzed for research studies to test and set parameters for third parties, such as government agencies for grant awards, public safety, quality control and quality assurance purposes.

Exemplary embodiments of the present disclosure include a method for evaluating one or more cannabis and cannabinoid products for use in a particular industry for research, public use, healthcare, or a combination thereof.

By way of example, an embodiment of the disclosure includes a distributed validated cannabis testing system. An embodiment of this system includes one or more processors, an input/output unit adapted to be in communication with the one or more processors, one or more cannabis databases in communication with the one or more processors to store and associate a plurality of regulatory guidelines with a plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product, one or more electronic interfaces positioned to display an online user report and defining one or more cannabis user interfaces; and non-transitory computer-readable medium positioned in communication with the one or more processors and having one or more computer programs stored thereon. The computer program includes a set of instructions that when executed by one or more processors cause the one or more processors to perform operations of generating the cannabis user interface to display to a user thereof one or more online cannabis user reports, the cannabis user interface allowing an input of a plurality of information associated with the user or with the cannabis product, determining whether the cannabis product meets the regulatory guidelines responsive to receiving the plurality of information associated with the user or with the cannabis product and information from the one or more cannabis databases, associating the plurality of regulatory guidelines with the plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product, and outputting to the one or more cannabis user interfaces the one or more online cannabis user reports, the cannabis user reports including one or more of the plurality of information associated with the user or with the cannabis product, and one or more of the plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product for research or for public use.

Embodiments of the disclosure advantageously provide, for example, sensors, distributed validated systems, computer-readable program products, and related methods to track cannabis and cannabinoid products from seed to consumer. The technology disclosed herein relies upon a blockchain-based transaction platform to access and track multiple transactions among various parties involved in manufacture and production of the cannabis products and its subsequent delivery for consumption. Any trusted individual or company can access the blockchain-based transaction platform to verify the information associated with any of the transaction records associated with a particular product.

Embodiments of the disclosure provide a distributed validated system and a method for integrating profiling and characterizing of the cannabis seed (genetics/multiomics), plant/growing process (cultivation), processing/manufacturing, information technology (IT)/software services, products, and medicaments. The embodiments disclosed herein facilitate safe administration to subjects and also provide a means of accessing therapeutic intervention outcomes. Embodiments of the disclosure provide methods of tracking, verifying, and validating a cannabis product through a platform with integrated and comprehensive management, i.e. a blockchain system, of that product.

Embodiments of the disclosure provide a method of managing information related to a cannabis product across a distributed validated system. The method includes enabling a first authorized user to create a first plurality of data containing genetic profile of a seed used for production of the cannabis product. The method includes associating the first plurality of data to a first record which is identified by a first unique identifier. The method includes storing the first record into a memory for access by one or more of a plurality of authorized users using the first unique identifier. The method includes enabling a second authorized user to create a second plurality of data containing plant growth conditions of a crop used for production of the cannabis product. The method includes associating the second plurality of data to a second record which is identified by a second unique identifier. The method includes storing the second record into the memory for access by the one or more of the plurality of authorized users using the second unique identifier. The method includes enabling a third authorized user to create a third plurality of data containing manufacturing information for production of the cannabis product. The method includes associating the third plurality of data to a third record which is identified by a third unique identifier. The method includes storing the third record into the memory for access by the one or more of the plurality of authorized users using the third unique identifier. The method includes analyzing the cannabis product to determine quality and quantity of desired components and undesired components in the cannabis product using one or more of: cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, quality control testing, and quality assurance testing. The method includes determining concentration of one or more cannabinoids in the cannabis product. The method includes enabling a fourth authorized user to create a fourth plurality of data containing measurements of the quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the fourth plurality of data to a fourth record which is identified by a fourth unique identifier. The method includes storing the fourth record into the memory for access by the one or more of the plurality of authorized users using the fourth unique identifier.

In some embodiments, each of the first identifier, the second identifier, the third identifier, and the fourth identifier provides access to one or more of: the first plurality of data, the second plurality of data, the third plurality of data, and the fourth plurality of data. In some embodiments, each of the first record, the second record, the third record, and the fourth record includes a timestamp. In some embodiments, each of the storing the first record step, the storing the second record step, the storing the third record step, and the storing the fourth record step is validated by the one or more of the plurality of authorized users. In some embodiments, the first plurality of data further includes one selected from the group consisting of: seed purchase request data, grower data, breeder data, seed purchase data, and combinations thereof. In some embodiments, the second plurality of data includes one selected from the group consisting of: seed planting data, soil data, weather data, water data, moisture data, pressure data, light data, nutrient data, pesticide data, microorganism data, toxicant data, crop growth data, harvesting data, storage data, and combinations thereof. In some embodiments, the third plurality of data includes one selected from the group consisting of: supply data, distribution data, extraction data, purification data, and combinations thereof. In some embodiments, the method further includes the step of comparing measurements of the quality and quantity of desired components and undesired components in the one or more cannabis products and the concentration of one or more cannabinoids against appropriate regulations for consumption of the cannabis product. The method further includes the step of certifying that the cannabis products satisfies or fails the appropriate regulations. In some embodiments, the method further includes the step of enabling a fifth authorized user to create a fifth plurality of data containing dose and dosage of the cannabis product provided to a consumer. The method further includes the step of associating the fifth plurality of data to a fifth record which is identified by a fifth unique identifier. The method further includes the step of storing the fifth record into the memory for access by the one or more of the plurality of authorized users using the fifth unique identifier. In some embodiments, the fifth identifier provides access to one or more of: the first plurality of data, the second plurality of data, the third plurality of data, the fourth plurality of data, and the fifth plurality of data. In some embodiments, the fifth record includes a timestamp. In some embodiments, the fifth plurality of data includes one selected from the group consisting of: physician data, pharmacist data, patient data, consumer data, imaging data, treatment data, treatment outcome data, and combinations thereof.

Embodiments of the disclosure provide a method of managing information related to a cannabis product across a distributed validated system. The method includes preparing a sample of the cannabis product. The method includes testing the sample to determine one or more parameters of: moisture content, microbe/pathogen/mycotoxin profile, pesticide and toxicant profile, residual solvents, heavy metal content, terpene profile, and cannabinoid profile. The method includes enabling an authorized user to create a plurality of data containing parameters obtained in the testing step. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. In some embodiments, the method further includes the step of storing the cannabis product over a predetermined period.

Several disadvantages were recognized by the inventors and various embodiments of this disclosure were developed to address these shortcomings in the art. Certain embodiments disclosed and described here include compositions containing a conjugate of a label, a chelator, and a cannabinoid analog. The label can be a radionuclide. The label can be one or more of Technetium-99, Gallium-68, Copper-60, Copper-64, Indium-Ill, Holmium-166, Rhenium-186, Rhenium-188, Yttrium-90, Lutetium-177, Radium-223, or Actinium-225. In certain embodiments, the label is configured to facilitate contrast-enhanced imaging, when the composition is administered to a mammal during use. The cannabinoid analog can be an immune check point cannabinoid receptor ligand. The cannabinoid analog can be a synthetic cannabinoid receptor agonist or a natural cannabinoid receptor agonist. The cannabinoid analog can be an aminoalkylindole. The cannabinoid analog can be a cannabinoid receptor inverse agonist. The cannabinoid analog can be a member of the group consisting of anandamide (AEA), 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine and N-arachidonylodopamine (NADA). The cannabinoid analog can be a diarylopyrazole. The chelator can an aminated or an acid chelator. In certain embodiments, the chelator is a cyclam. The cannabinoid analog can be cyclam-1′-acetyl-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide. The cannabinoid analog can be cyclam-1′-propyl-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide.

Embodiments also include methods for diagnosing a medical condition in a human subject, by administering to a human subject in need thereof an effective amount of any of the compositions described herein. A method of imaging a plurality of cancer cells, the method comprising administering to a human patient an effective amount of any of the compositions described herein. Embodiments also include methods for treating a cancer amenable to treatment with a cannabinoid, the method comprising administering to a human subject in need thereof an effective amount of any of the compositions described herein. Embodiments also include methods for treating a neurologic disorder amenable to treatment with a cannabinoid, the method comprising administering to a human subject in need thereof an effective amount of any of the compositions described herein. Embodiments also include methods for alleviating pain in a human subject, the method comprising administering to a human subject in need thereof an effective amount of the composition of any of the compositions described herein. Embodiments also include kits for imaging cells, comprising a predetermined quantity of a conjugate of a chelator and a medical cannabinoid analog; and a predetermined quantity of an imaging agent. The conjugate of the chelator and the medical cannabinoid analog can be present in the kit as precursors that subsequently interact with the imaging agent, when provided with suitable reaction conditions. The kit can include a tin-containing reducing agent. Cells, organs, and tissues that can be imaged using the kits include those of the cardiovascular system, precancerous cells and tissues, cancerous cells and tissues, and cells and tissues of the nervous system, including the brain and the spinal cord.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the manner in which the features and benefits of the disclosure, as well as others which will become apparent, may be understood in more detail, a more particular description of the embodiments of the disclosure may be had by reference to the embodiments thereof which are illustrated in the appended drawings, which form a part of this specification. It is also to be noted, however, that the drawings illustrate only various embodiments of the disclosure and are therefore not to be considered limiting of the disclosure's scope as it may include other effective embodiments as well.

FIG. 1 is a schematic block diagram of an exemplary method according to an embodiment.

FIG. 2 is a schematic block diagram of an exemplary method according to an embodiment.

FIG. 3 is a schematic diagram of an exemplary system according to an embodiment.

FIG. 4 is a schematic block diagram of an exemplary system according to an embodiment.

FIG. 5 is a schematic block diagram of an exemplary method according to an embodiment.

FIG. 6 is a schematic block diagram of an exemplary method according to an embodiment.

FIG. 7 is a representative analysis of starting material SR141716 (rimonabant) using NMR spectroscopy, according to an embodiment.

FIG. 8 is a representative analysis of starting material SR141716 using high-performance liquid chromatography (HPLC) analysis, according to an embodiment.

FIG. 9 is a representative analysis of VYR206 using NMR, according to an embodiment.

FIG. 10 is a representative analysis of VYR206 using mass spectrometry, according to an embodiment.

FIG. 11 is a representative analysis of VYR206 using HPLC analysis, according to an embodiment.

FIGS. 12A-12C show the protein expression of the CBi receptor using Western blot analysis. FIG. 12A panel shows expression of the CBi receptor in cell lysate from various DLBCL.

FIG. 12B shows expression of β-actin as the control for sample loading. FIG. 12C is a graphical representation of the mRNA expression analysis of CBi and CB₂ in various DLBCL cancer cell lines.

FIG. 13 is a graphical representation of the efficacy of cannabinoid receptor ligand SR141716 (rimonabant) on diffuse large B-cell lymphoma (DLBCL) cell lines' viability.

FIG. 14 is a graphical representation of the efficacy of cannabinoid receptor ligand CP945,598 (Otenabant) on DLBCL cell lines' viability.

FIG. 15 is a graphical representation of the efficacy of cannabinoid receptor ligand AM1241 on DLBCL cell lines' viability.

FIG. 16 is a graphical representation of the efficacy of cannabinoid receptor ligand AM251 on DLBCL cell lines' viability.

FIGS. 17A-17D are graphical representations of the inhibition efficacy of two CBi inverse agonist SR141716 and VYR206 using DLBCL (FIGS. 17, A and B) and mantle cell lymphoma (MCL) cell lines (FIG. 17, Panels C and D).

FIGS. 18A-18D are graphical representations of the inhibition efficacy response of two selected CBi inverse agonist SR141716 and VYR206 and N4 using cell viability assays on DLBCL cancer cells: LR, MS, RC and DOHH2.

FIGS. 19A-19D are graphical representations of the inhibition efficacy response of two selected CBi inverse agonist SR141716 and VYR206 and N4 using cell viability on MCL cancer cells: Jeko, Mino, Rec-1 and JMP1.

FIGS. 20A-20C are graphical representations of the high through put screening assessment of cell viability in 16 DLBCL (FIGS. 20A and B) and 8 MCL (FIG. 20C) cancer cell lines using cannabidiol, which was obtained as CBD in a coconut oil extract.

FIGS. 21A-21D show the expression of CBi and CB₂ RNA in MCL and DLBCL cancer cell lines treated with VYR206 and CBD using immunoblot analysis. FIG. 21A panel shows expression of CBi with treatment with VYR206. FIG. 21B panel shows expression of CB₂ with treatment with VYR206. FIG. 21C panel shows expression of CB₂ with treatment with CBD. FIG. 21D panel shows expression of β-actin as the control for sample loading.

FIGS. 22A-22B are graphical representations of the efficacy of a cannabidiol (CBD-99) on MCL and DLBCL cell lines' viability. FIG. 22A is a graphical representation of the efficacy of CBD on MCL cell lines. FIG. 22B is a graphical representation of the efficacy of CBD on DLBCL cell lines.

FIG. 23 is a graphical representation of IC50 of rimonabant (identified as Rimo) versus Bruton's tyrosine kinase inhibitor-ibrutinib (II3N) on various DLBCL cell lines.

FIGS. 24A-24D are graphical representations of the effect of the cannabinoid receptor ligand-rimonabant (identified as Rimo) and a Bruton's tyrosine kinase inhibitor-ibrutinib (identified as IBN) on the viability of MCL cell lines (Jeko, Jeko-R, Mino, Mino-R, PF-4 and PF-5) cell lines' viability. FIG. 24A is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on Jeko and Jeko-R cell lines. FIG. 24B is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on Mino and Mino-R. FIG. 24C is a graphical representation of efficacy of ibrutinib on PF-4 and PF-5 cell lines. FIG. 24D is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on PF-4 and PF-5.

FIGS. 25A-24H are graphical representations of the efficacy of rimonabant and its cyclam conjugated form, VYR206 on the viability of DLCBL cell lines (LR, MS, RC and DOHH2) and MCL cell lines (Jeko, Rec-1, Mino and JMP-1). FIG. 25A is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of LR cell line with cyclam as a control. FIG. 25B is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of MS cell line with cyclam as a control. FIG. 25C is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of RC cell line with cyclam as a control. FIG. 25D is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of DOHH2 cell line with cyclam as a control. FIG. 25E is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Jeko cell line with cyclam as a control. FIG. 25F is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Rec-1 cell line with cyclam as a control. FIG. 25G is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Mino cell line with cyclam as a control. FIG. 25H is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of JMP-1 cell line with cyclam as a control.

FIGS. 26A-26D are graphical representations of the effect of a cannabidiol (CBD-99) on the viability of DLBCL (RC) and MCL (Mino) cell lines, individually and in combination with four chemo therapeutics: Bruton's tyrosine kinase inhibitors-ibrutinib (IBN) and zanubrutinib (BGB); proteasome inhibitor-carfilzomib (CFZ); and chemotherapeutic agent-tumorex (TMX). FIG. 26A is a graphical representation of the effect of 25 μM of CBD-99 and IBN, individually and in combination, on the viability of Mino and RC cells. FIG. 26B is a graphical representation of the effect of 6 μM of CBD-99 and 10 nM of CFZ, individually and in combination, on the viability of Mino and RC cells. FIG. 26C is a graphical representation of the effect of 25 μM of CBD and BGB, individually and in combination, on the viability of Mino and RC cells. FIG. 26D is a graphical representation of the effect of 12.5 μM of CBD and 250 nM of TMX, individually and in combination, on the viability of Mino and RC cells.

FIGS. 27A-21E show the expression of cleaved PARP (cPARP) and cleaved caspase-3 expression with increasing treatment of cannabidiol and VYR206 to demonstrate activation of apoptosis using immunoblot analysis. FIG. 27A panel shows expression of cPARP with increasing levels of cannabidiol and VYR206. FIG. 27B panel shows expression of β-actin as the control for sample loading. FIG. 27C panel shows expression of cPARP with increasing concentration of cannabidiol. FIG. 27D panel shows expression of cleaved caspase-3 with increasing concentration of cannabidiol. FIG. 27E panel shows expression of β-actin as the control for sample loading.

FIGS. 28A-28B are graphical representations of the efficacy of cannabidiol, VYR206 (identified as N4-Rimo) and the combination of cannabidiol and VYR206 on the viability of DLCBL cell lines. FIG. 28A is a graphical representations of the efficacy of cannabidiol, VYR206, and the combination of cannabidiol and VYR206 on the viability of DLCBL cell line-LY19. FIG. 28B is graphical representations of the efficacy of cannabidiol, VYR206 (identified as N4-Rimo) and the combination of cannabidiol and VYR206 on the viability of DLCBL cell line LR.

FIG. 29 is a heat map of the changes in gene expression in RC cell line following treatment with rimonabant.

DETAILED DESCRIPTION

The present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, which illustrate various embodiments of the disclosure. This disclosure, however, may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art. It is to be fully recognized that the different teachings of the various embodiments discussed below may be employed separately or in any suitable combination to produce desired results. The various characteristics mentioned above, as well as other features and characteristics described in more detail below, will be readily apparent to those skilled in the art upon reading the following detailed description of the various embodiments, and by referring to the accompanying drawings. In the drawings and description that follow, like parts are marked throughout the specification and drawings with the same reference numerals, respectively. Certain features of the disclosure may be shown exaggerated in scale or in somewhat schematic form and some details of conventional elements may not be shown in the interest of clarity and conciseness.

The disclosure may use the phrases “in some embodiments,” “in various embodiments,” “in certain embodiment,” or “in embodiments,” which may each refer to one or more of the same or different embodiments. Furthermore, the terms “comprising,” “including,” “having,” and the like, as used with respect to embodiments of the present disclosure, are synonymous.

Exemplary embodiments of the present disclosure advantageously provide, for example, sensors, systems, computer-readable program products, and related methods to track cannabis and cannabinoid products from seed to consumer. The technology disclosed herein relies upon a blockchain-based transaction platform to access and track multiple transactions among various parties involved in manufacture and production of the cannabis products and its subsequent delivery for consumption. Any trusted individual or company can access the blockchain-based transaction platform to verify the information associated with any of the transaction records associated with a particular product.

Embodiments include theranostics compositions containing label-chelator-medical cannabinoid analog conjugates. The labels can be radionuclides that are used to label a medical cannabinoid analog through a chelator. Certain embodiments include cyclam (N4) as the chelator.

As used herein, the term “blockchain” refers to a time-dependent growing list of immutable informational objects or records (hereinafter referred to as “blocks”) that are linked via cryptography. As used herein, the term “time-stamp” refers to a sequence of characters or encoded information identifying when a certain event occurred. The timestamp includes digital date and time information that can be attached to the block. As used herein, the terms “hash” or “hash value” refer to a value resulting from a hash function, which is a function used to map certain data having an arbitrary size to data of a finite size. The hash is a unique identifier associated to a block, and is a key element of the distributed validated system described here. Typically, each block is associated with a timestamp, a hash of the then current block, and a hash associated with the immediately recent block of the then current block.

A seed, as used herein, refers to a unit of reproduction of a plant of the Cannabis genus, capable of developing into another such plant. The term is used here to include both a seed that is created by sexual propagation and a cutting or a clone that is an asexual propagation unit. As used herein, a cannabis product or a cannabinoid product includes, but is not limited to, any useable product legally intended for research or for human consumption, and containing one or more of Δ-9-tetrahydrocannabinol, 8-tetrahy-drocannabinol, cannabichromene, cannabicyclol, cannabidiol, cannabielsoin, cannabigerol, cannabinidiol, cannabinol, cannabitriol, and cannabidiolic acid. Cannabis products can include two or more of these cannabinoids in varying proportions. Cannabis products can include products that are infused with one or more of the above-identified cannabinoids and are legally intended for human consumption. Cannabis products can include products obtained from naturally occurring or genetically modified plants that are scientifically identified as Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Cannabis products can include products synthesized in a laboratory and containing one or more of Δ-9-tetrahydrocannabinol, 8-tetrahydrocannabinol, cannabichromene, cannabicyclol, cannabidiol, cannabielsoin, cannabigerol, cannabinidiol, cannabinol, cannabitriol, cannabidiolic acid, nabilone, and endocannabinoids like 2-archidonoylglycerol, n-archidonoyldopamine, virodhamine, and noladin ether. A cannabis product can include products that are processed to include one or more of the sixty different cannabinoids that have been identified in samples of cannabis obtained from naturally occurring or genetically modified plants that are scientifically identified as Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Embodiments of the disclosure also include the testing of cannabinoid products that are isolated from cannabis and documentation of the information as a block. Accordingly, a cannabis product as used herein further includes products that include one or more cannabinoids isolated from cannabis. Cannabis products can come in a variety of forms, including: as a dried plant, resin, in powder form, as oil, as products for smoking, as vaporized products, and also as cannabis-infused teas, candies, cookies, and brownies. Cannabis products can contain cannabis compounds derived from natural sources or otherwise and incorporated along with organic or inorganic components, including, but not limited to, natural, polar, or non-polar solvents. Cannabis products can be used for medicinal purposes, research purposes, recreational purposes, or for a combination thereof.

A cannabis product or a cannabinoid product includes, but is not limited to, cannabinoid analogs. As used herein, the term “cannabinoid analog” refers to a compound capable of either interacting with cannabinoid receptors in a subject or sharing chemical similarity with cannabinoids or both. Cannabinoid analogs include synthetic or natural cannabinoid compounds that can function as agonists or antagonists. Embodiments of cannabinoid analogs include, but are not limited to, cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethylester (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic acid (CBDA), cannabidivarin (CBV), cannabidiorcol (CBD-C1), tetrahydro-cannabinol (THC), N-arachidonoylethanolamine (AEA) or anandamide, 2-arachidonoylglycerol (2-AG), rimonabant, AM6538, taranabant, otenabant, cannabigerolic acid monomethylether (CBGAM), cannabigerol monomethylether (CBGM), cannabigerovarin (CBGV), cannabigerovarinic acid (CBGVA), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid CBCVA), cannabichromevarin (CBCV), Δ-9-tetrahydrocannabinolic acid A (THCA-A), Δ-9-tetrahydrocannabinolic acid B (THCA-B), Δ-9-tetrahydrocannabidiol (THC), Δ-9-tetrahydrocannabinolic acid-C4 (THC-C4), Δ-9-tetrahydro-cannabivarinic acid (THCVA), Δ-9-tetrahydrocannabivarin (THCV), Δ-9-tetrahydrocannabiorcolic acid (THCA-C1), Δ-9-tetrahydrocannabiorcol (THC-C1), Δ-7-cis-isotetrahy-drocannabivarin (THCV), Δ-8-tetrahydrocannabinolic acid (Δ-8-THCA), Δ-8-tetrahydrocannabidiol (Δ-8-THC), cannabicyclolic acid (CBLA), cannabicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-A), cannabielsoin (CBEA-A), cannabinolic acid (CBNA), cannabinol (CBN), cannabinol methylether (CBNM), cannabinol-C4 (CBN-C4), cannabi-nol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol, 8,9-dihy-droxy-Δ-6a-tetrahydrocannabinol, cannabitriolvarin (CBTV), and ethoxy-cannabitriolvarin (CBTVE).

A cannabis product or a cannabinoid product includes, but is not limited to, theranostic compositions containing label-chelator-medical cannabinoid analog conjugates. The labels can be radionuclides that are used to label a medical cannabinoid analog through a chelator. Certain embodiments include cyclam (N4) as the chelator. As used herein, the term “theranostic” refers to agents or applications that can function in both diagnostic and therapeutic modalities.

As used herein, the term “chelators” refer to compounds that form coordination complexes upon binding with metal ions or other substrates. The structure of chelating ligands and the metals that are chelated to them may be varied depending on the desired use. Many ligands that bind to radionuclide metals are tetradentate and contain a combination of four nitrogen and/or sulfur metal coordinating atoms (i.e. N4, N3S, N2S2 and the like). Example of chelators that can be used here includes cyclam compounds (N4), diethylentriamine pentaacetic acid (DTPA), tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), eth-ylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid (DMSA), sulfur colloid, and N2S2 systems such as MAMA (monoamidemonoaminedithiols), DADS (N2S2 diaminedithiols), CODADS and the like. These chelator systems and a variety of others are described in Liu and Edwards, Chem Rev. 1999, 99 (9), 2235-2268; N₂S₂ is also described in U.S. Pat. Nos. 4,897,225; 5,164,176; or 5,120, 526. Method for synthesis of certain N4 compounds is described in U.S. Pat. No. 5,880,281 but they can also be obtained from commercial sources such as Sigma Aldrich Chemical (Milwaukee, Wis.) and TCI America (Portland, Oreg.). Certain N4 compounds which can be used as chelators may include but not limited to, 1,4,7,10-tetraazacy-clododecane (Cyclen), 1,4,7,10-tetraazacyclotridecane (Cyclam 13), 1,4,7,11-tetraazacyclotetradecane (Isocyclam), 1,5,9,13-tetraazacyclohexadecane, 1,5,9,13-tetraazacyclo-heptaadecane, 1,5,9,14-tetraazacyclooctadecane, 1,5,10,14-tetraazacyclooctadecane, 1,5,10,15-tetraazacyclodononade-cane, which are described in U.S. Pat. Nos. 8,758,723, 6,093,382; 5,608,110; 5,665,329; 5,688,487, U.S. Pat. Pub. No. 2012/0276005, and PCT/GB2005/002807. Other examples of chelator moieties include but not limited to, tetraazacyclododecane-N,N′,N″,N′″-tetra-acetic acid, mono-amide (DOTA-MA); 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A). N4 is conjugated to a medical cannabinoid compound and further chelated to a metal. N4 has a closed-ring structure that helps stabilize the radionuclides. Chelators with higher lipophilicity, such as N4, also confer decreased renal and hepatic toxicity because they have shown decreased accumulation in these organs, resulting from greater uptake by the targeted cells. Conjugation of DOTA to highly selective CB₂ receptor inverse agonist SR144528 following by chelation of Gallium (Ga), Technetium (Tc), Copper (Cu) or with lanthanide series such as Gadolinium (Gd), Europium (Er), Terbium (Tb) is described in U.S. Pat. No. 8,367,714. Imaging CB₁ receptor using various radiotracers is described in PCT/US2009/043491. Radioligands with high affinity and selectivity for CBi receptors such as 3,4-diarylpyrazoline derivatives were labeled a radioisotope selected from the group consisting of ²H, ¹⁴C, ¹³N, ¹⁸F, ⁷⁵Br, ⁷⁶Br, and ¹²³I for imaging with PET or SPECT. U.S. Pat. Nos. 8,840,865, 9,617,215, 8,323,621, U.S. Pat. Pub. No. 2005/0070596, and WO2007130361 describe imaging of cannabinoid system for medical and therapeutic purposed to treat for instance inflammatory diseases, cancer, neurological disorders therapeutics and medical imaging.

As used herein, the term “label” refers to an atom, a molecule, or a compound that is used to identify the location of the composition to which the label is attached. Labels can have one or more of fluorescent, phosphorescent, luminescent, electroluminescent, chemiluminescent or other spectroscopic properties. These properties enable the detection and identification of the label-chelator-medical cannabinoid analog conjugates using any technique capable of detecting and identifying the label, including visible light, ultraviolet and infrared spectroscopy, Raman spectroscopy, nuclear magnetic resonance, positron emission tomography, and other methods known in the art.

As used herein, the term “imaging” refers to all tissue visualization processes using electromagnetic wave technologies for which the instant compositions can be used, including but not limited to cells of the nervous system, blood cells, cancerous cells, and precancerous cells. Provided here are kits for imaging neurologic cells. In an embodiment, the kit contains a predetermined quantity of a conjugate of a chelator and a medical cannabinoid analog; and a predetermined quantity of an imaging agent. The conjugate of the chelator and the medical cannabinoid analog can be present in the kit as precursors that subsequently interact with the imaging agent, when provided with suitable reaction conditions. The kit can also include a tin-containing reducing agent. Also provided here are kits for genomic or other omic assays that contain a predetermined quantity of a conjugate of a chelator and a medical cannabinoid analog; and a predetermined quantity of an imaging agent.

As used herein, the terms “radionuclide,” “radioactive nuclide,” “radioisotope,” or “radioactive isotope” are synonymous. One or more different radioisotopes can be used as labels. The non-limiting examples of radionuclides include ^(99m)Tc, ^(117m)Sn, ¹⁷⁷Lu, ¹⁸⁸Re, ¹⁸⁶Re, ¹⁵³Sm, ¹⁶⁶Ho, ⁹⁰Y, ⁸⁹Sr, ⁶⁷Ga, ⁶⁸Ga, ¹¹¹In, ¹⁸⁶Gd, ⁵⁹Fe, ²²⁵Ac, ²¹²Bi, ²¹¹At, ⁴⁵Ti, ⁶⁰Cu, ⁶¹Cu, ⁶⁷CU, ⁶⁴Cu and ⁶²Cu. In other aspects, the metal ion is a non-radioactive metal such as ¹⁸⁷Re, ⁶⁹Ga, and ¹⁹³Pt.

A cannabis product that is evaluated under embodiments of the disclosure can be received from a variety of sources, including, but not limited to, growers, farmers, producers and processors of the cannabis products and wholesale and retail sales entities of the cannabis products. As used herein, producers include a person or an entity authorized by a state or federal control board or agency to grow, plant, cultivate, harvest, or be similarly involved in production of naturally occurring or genetically modified plants that are scientifically identified as Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Producers also include a person or an entity authorized by a state or federal control board or agency to procure raw materials, and chemically manufacture, or be similarly involved in production of cannabis products.

As used herein, a processor of a cannabis product can include, but is not limited to, a person or an entity authorized by a state or federal control board or agency to process naturally occurring or chemical raw materials to produce cannabis products, package and label cannabis products for sale in retail outlets, and sell cannabis products to wholesale and retail sales entities.

As used herein, a retail sales entity of a cannabis product can include, but is not limited to, a person or an entity authorized by a state or federal control board or agency to sell cannabis products in a retail outlet. As used herein, a retail outlet can include, but is not limited to, a location authorized by a state or federal control board or agency for the retail sale of cannabis products. For example, without limitations, federal agencies such as the US Department of Agriculture, the Food and Drug Administration, and the Drug Enforcement Agency can regulate the consumption of the cannabis products and provide the required guidelines for testing the cannabis products. For example, without limitations, retail sales entities in the state of Washington include entities that sell cannabis products under a license from the Washington Liquor Control Board. For example, without limitations, retail sales entities in the state of Colorado include entities that sell cannabis products under a license from the Marijuana Enforcement Division.

As used herein, users can include, but are not limited to, persons or entities who use or benefit from certain embodiments of the disclosure by receiving information regarding the cannabis products. Users can also include producers of the plant, manufacturers and distributors of the cannabis products, researchers or healthcare professionals at government and private entities, and wholesale and retail sales entities of the cannabis products. Users can also include persons or entities who receive through legal means the cannabis products from producers of the plant, manufacturers and distributors of the cannabis products, and wholesale and retail sales entities of the cannabis products. Users can also include, but are not limited to, people who consume the cannabis product for medicinal or recreational purposes, or for any legally approved reason. Users can also include, but are not limited to, individuals who are employees or agents of governmental agencies (such as researchers whom may be performing studies for non-human or human use), and have a legal reason to access the information associated with the cannabis products. As used herein, the term “subject” refers to all kinds of animals including humans, rodents, other mammals, or avian species. The cannabinoid-based compositions can serve as a diagnostic agent, a prognostic agent, or an agent to alleviate or treat a disease in a subject. The target site can be any tissue of the subject, including but not limited to the brain, heart, lung, esophagus, intestine, breast, uterus, ovary, prostate, testis, stomach, bladder, or liver. Also, embodiments provided herein can be used as agents to target diseases, such as cancer or neurologic, gastrointestinal, metabolic, and neuroendocrine disorders. As used herein, the term “administration” refers to an activity of introducing a composition described herein to a subject by an appropriate method, and the composition may be administered via various routes of intravenous, oral, intramuscular, transdermal, intra-peritoneal, topical, sublingual, buccal, inhalation, nasal, or ophhalmic routes as long as they can deliver the same to the target tissues. The compositions described herein can be delivered as pharmaceutical formulation.

As used herein, users can include, but are not limited to, persons or entities who are involved in the generation and use of specific cannabis products for precision medicine. For example, these specific cannabis products include theranostic compositions that target the endo-cannabinoid system (ECS) implicated in the pathogenesis of neurologic disorders and cancer. This individualized medicine platform allows delivery of personalized medicines designed on the basis of individual genetic make-up, biochemistry, molecular imaging, molecular blueprint, and clinical observations and measurements associated to each patient's disease. In another example, these specific cannabis products are part of compositions for imaging or treatment of diseased cells. Certain compositions contain a cannabinoid analog and a chemotherapeutic agent. Certain composition contain a chemotherapeutic agent and a cannabinoid analog conjugated to a chelator. In certain embodiments, the chelator is cyclam. In certain embodiments, the cannabinoid analog is a cannabidiol. Certain embodiments include compositions containing a combination of a chemo-therapeutic agent and a cannabinoid analog conjugated to a chelator and a label. In certain embodiments, the chemo-therapeutic agent is Bruton's tyrosine kinase inhibitors, such as ibrutinib (IBN) and zanubrutinib (BGB). In certain embodiments, the chemotherapeutic agent is a proteasome inhibitor, such as carfilzomib (CFZ). In certain embodiments, the chemotherapeutic agent is tumorex (TMX).

Information regarding the cannabis products involve any or some or all information associated with origin, efficacy, potency, quality and quantity of desired components and undesired components in the cannabis products, the governmental licenses and authorizations for the cannabis products, therapeutic outcomes following administration or consumption of such products, or any combinations of the information thereof. Desired components in cannabis products include, without limitations, chemical components and biological components of a cannabis product that allow the cannabis product to meet the requirements for sale or for human consumptions in a particular industry. Desired components, for example without limitations, include cannabinoids, pharmaceutically acceptable salts, pharmaceutical fillers, taste additives, and food coloring. Undesired components in cannabis products can include, without limitations, chemical components and biological components of a cannabis product that cause the cannabis product unfit for sale in a particular industry. Undesired components, for example without limitations, include pathogenic microorganisms and toxic chemicals like pesticides, fertilizers, and plant growth regulators. Desired components in a cannabis product in a particular industry may be undesired components in another industry. As used herein, the term “pharmaceutically acceptable salt” refers to those salts, which retain the biological effectiveness and properties of the parent compound. And unless otherwise indicated, a pharmaceutically acceptable salt includes salts of acidic or basic groups, which may be present in the compounds of the formulae disclosed herein. Certain cannabis products include conjugates of a chelator and a targeting ligand. Such products may be used for imaging, diagnostic and/or therapeutic purposes.

In certain embodiments, the cannabis product that is tracked through the distributed validated cannabis testing system is a pharmaceutical formulation. A “pharmaceutical formulation” refers to a mixture of one or more of the compounds described herein, or a pharmaceutically acceptable derivative as an active ingredient, and at least one pharmaceutically acceptable carrier or excipient. The purpose of a pharmaceutical composition is to facilitate administration of a compound to a subject. In another aspect, a pharmaceutical composition can contain a compound of one of the formulae described herein, or a pharmaceutically acceptable derivative, and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition includes two or more pharmaceutically acceptable salts, acids, esters, excipients, carriers, diluents, and combinations thereof. The term “pharmaceutically acceptable derivative” as used herein refers to and includes any pharmaceutically acceptable salt, pro-drug, metabolite, ester, ether, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, upon administration to a subject, is capable of providing (directly or indirectly) the active ingredient. For example, the term “a pharmaceutically acceptable derivative” of compounds described herein includes all derivatives of the compounds described herein (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, and adducts) which, upon administration to a subject, are capable of providing (directly or indirectly) the compounds described herein.

For example, the cannabis products being tracked through the distributed validated cannabis testing system include cannabinoid-based compositions used for imaging diseased cells. These compositions can be applied in the diagnosis, assessment, and treatment of any medical disorder and the information associated with the subjects receiving these compositions is also an input into the distributed validated cannabis testing system. The diseases may include various forms of neurologic disorders and cancer. In particular, cancer can include one or more carcinoid, neuroen-docrine cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head and neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, colorectal cancer, and cancers of hematopoietic origin such as lymphoma, or leukemia. The neurologic diseases can include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis, posttraumatic stress disorder (PTSD), epilepsy, seizures, Tourette's syndrome, schizophrenia, anxiety disorders, autism, depression, dementia, and other diseases and disorders that implicate the nervous system.

The distributed validated cannabis testing system also includes blocks from users of the imaging modalities using these cannabis products, and containing information such as sensitivity and specificity, patient administration issues, and adverse effects. Other information can also include the time and costs data associated with any of the foregoing. Health professionals can access blocks of information to track the particular cannabis product that has been administered to the subject. The professionals can also input and access information related to the diagnosis, prognosis, and treatment of the patient, especially when that patient is being treated or under treatment with medical cannabinoids. Certain embodiments include methods of imaging at the site of a disease in a given subject to perform a pre- or post-treatment evaluation and to be able to monitor that subject for as long as that subject is being treated or under treatment with medical cannabinoids. In certain embodiments, the diagnostic laboratory systems also provide data to the distributed validated cannabis testing system. Accordingly, any imaging modality can be used to detect signals from the one or more labels. Non-limiting examples of imaging methods used to detect the signals from the labels include PET, PET/CT, CT, SPECT, SPECT/CT, Mill, near-infrared (NIR), optical imaging, optoacoustic imaging, and ultrasound.

The distributed validated cannabis testing system also includes blocks from manufacturers of kits that contain an imaging probe, a diagnostic agent, or a pharmaceutical composition. Certain specific embodiments include blocks from systems involved in imaging, testing, diagnosing, or delivering a cannabis-based composition for the treatment of physiological disorders. Authorized users of the distributed validated cannabis testing system can access and provide input regarding the personalized and efficacious dose and dosing regimens involving the use of medical cannabinoids.

The distributed validated cannabis testing system also includes blocks from manufacturers, suppliers, and distributors of the cannabinoid-based compositions, such as the label-chelator-medical cannabinoid analog conjugates. These conjugates can include phytocannabinoids that are naturally occurring plant-derived cannabinoids. The manufacturers, suppliers, and distributors of the medical cannabinoids are involved in the manufacturing, extraction, purification, and distribution of these naturally occurring compounds that are isolated from plants. The cannabinoid-based compositions also include label-chelator-terpenoid analog conjugates, label-chelator-flavonoid conjugates, and label-chelator-phytosterol conjugates. Among the natural medical phytocannabinoids, Δ-9-tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD), and cannabinol (CBN) are the most abundant, yet other phytocannabinoids can play a very important role in precision medicine. Based on structure, binding properties and signaling/function features, medical cannabinoids are grouped into distinct classes: (i) the classical medical cannabinoids, which include both natural plant extracts such as Δ-9-THC and chemically synthesized compounds such as Marinol; (ii) nonclassical medical cannabinoids, mainly exemplified by the synthetic cannabinoid receptor (CB) agonist CP-55,940; (iii) aminoalkylindoles, which include chemically produced cannabinoids like AM1241; (iv) diarylopyrazoles, which include CB inverse agonists (or antagonists) such as SR141716A, also known as rimonabant; and (v) endogenous endocannabinoids, which are naturally produced by animal and human cells and include N-arachidonoylethanolamine, (AEA) or anandamide, 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine and N-arachidonylodopamine (NADA). Examples of the label-chelator-medical cannabinoid analog conjugate include the medical cannabinoids, such as dronabinol, nabilone, nabiximols, cannador, cannabidiol, cannabinol, cannabigerol, tetrahydrocannabivarin, and cannabi-chromene. Examples of the label-chelator-medical cannabinoid analog conjugate include medical cannabinoids such as HU-210, Δ-9-THC, Δ-8-THC and desacetyl-L-nantradol, which are recognized as CB1/CB2 receptor agonists, without distinctive specificity for either receptor. Δ-9-THC stands out as a C. sativa cannabinoid, which exhibits CB1/CB2 affinity and the highest psychotropic effects. By a pentyl substitution on Δ-8-THC side chain, conversion into the HU-210 analog occurs, with increased receptor affinity. Other structural modifications of the THC backbone lead to new and selective CB2 agonists JWH-133, JWH-139, and HU-308 and L-759633 and L-759656, which display affinities at the nanomolar range. Examples of the label-chelator-medical cannabinoid analog conjugate include non-classical medical cannabinoids, which are a family of bicyclic (AC) and tricyclic ACD medical cannabinoids. They are prominently represented by CP55940, along with CP55244 and CP47497 analogs. Of note, CP55940 is the best-known medical cannabinoid agonist, which displays a potent in vivo effect via shared CB1 and CB2 signaling. Examples of the label-chelator-medical cannabinoid analog conjugate include aminoalkylindoles. R-(+)-WIN55212 is the prototype of this family with medical cannabinoid-like features, which can bind both CB1 and CB2 receptors but exhibits higher specificity for CB₂ and can mimic in vivo THC-mediated effects. Other analogs like JWH-015 and L-768242 also show similar CB₂ affinity as R-(+)-WIN55212. Examples of the label-chelator-medical cannabinoid analog conjugate include medical diarylpyrazoles, which are a class of medical cannabinoid analogs whose distinctive function is to inhibit CB1 or CB2-dependent intracellular signaling pathways, acting as antagonists (inverse agonist); for example, embodiments include SR141716A, AM251 and AM281 that inhibit CB1 receptor mediated effects. Examples of the label-chelator-medical cannabinoid analog conjugate can include certain endocannabinoids. N-arachidonoylethanolamine (AEA), or Anandamide, is an example of an eicosanoid that is converted into its active form, via the omega-3 (ω-3) and omega-6 (ω-6) biosynthetic fatty acid pathways, and specifically targets CB receptors in mammals. Consequently other eicosanoids that can function in these embodiments include methanandamide (R and S isomers), arachidonyl-2-chloroethylamide (ACEA), arachidonylcyclopropylamide (ACPA) and 2-arachidonoylglycerol (2-AG), which exhibit binding affinity to CB1 and CB2.

The distributed validated cannabis testing system also includes blocks from systems used by consumers, patients, and healthcare professionals, who utilize medical cannabinoid-based compositions as theranostic agents targeting serious pathologies, such as cardiovascular, neurological, psychiatric, immunological, endocrine and neoplastic disorders. For example, authorized users of the distributed validated cannabis testing system can access and input information regarding the impact of the medical cannabinoid-based compositions in health and disease and the early success or failure for specific applications. In a specific example, authorized users of the distributed validated cannabis testing system can access and input information regarding the effect of the specific medical cannabinoid analog in the management of chronic pain.

For example, authorized users of the distributed validated cannabis testing system can access and input information regarding the ECS and other pathways that modulate parallel functions aimed at protecting and maintaining a subject's homeostasis. CB1 is mainly expressed in central and peripheral nervous system but discrete distribution has been observed in other tissues. Thus, utilization of the label-chelator-medical cannabinoid analog conjugates directed to CB1 signaling can result in broad and pleiotropic actions. Although the CB1 receptor has been known to primarily regulate functions associated to cognition, memory, perception, mood, behavior and psychotropic activities, there is increasing evidence that it can play a role in analgesia, cardiovascular, respiratory, and reproductive functions, as well in the maintenance of overall homeostasis. CB2 receptors are predominantly expressed in immune competent organs where cells undergo antigen-dependent maturation and selection programs, which empowers them to survey and mount powerful responses against pathogens and aberrantly developed cells. CB2 exhibits a relatively limited distribution in the central nervous system (CNS). CB2-dependent activation involves regulatory mechanisms that support immune cell migration to the site of inflammation and the release cytokines. The expression of CB₂ is particularly important for CNS microglia, as demonstrated by the capacity of medical cannabinoid agents to reduce cytokine-mediated neuro-inflammation. Embodiments of the label-chelator-medical cannabinoid analog conjugate that include specific CB2 ligands, such as 0-3223 (a synthetic CB2 specific agonist), can be used for anti-inflammatory and anti-nociceptive applications, without apparent CB1-like mediated effects.

For example, authorized users of the distributed validated cannabis testing system can access and input information regarding the manufacture, distribution, supply, administration and use of compositions containing the label-chelator-terpenoid conjugates and contribute to the block-chain with information about the antioxidant, anti-inflammatory, analgesic, anticancer, antibiotic and anti-psychiatric (anxiety and depression) benefits of terpenoid compounds. For example, authorized users of the distributed validated cannabis testing system can access and input information regarding the manufacture, distribution, supply, administration and use of compositions containing the label-chelator-flavonoid conjugates and contribute to the blockchain with information about the antioxidant, anti-inflammatory and anticancer properties of flavonoid compounds, including polyphenol cannabis flavonoids. The cannabis flavonoids can provide significant cardiovascular protection, particularly improving coronary and peripheral circulation by maintenance of homeostatic blood pressure, prevention of the formation of blood clots, and reduction of atherosclerosis risks. Mechanisms of cannabis flavonoids mediated antioxidative and anti-inflammatory effects include apigenin (4′,5,7-trihydroxyflavone)-dependent inhibition of TNF-α, which has also shown to exhibit therapeutic benefits in multiple sclerosis and rheumatoid arthritis. For example, authorized users of the distributed validated cannabis testing system can access and input information regarding the manufacture, distribution, supply, administration and use of compositions containing the compositions containing the label-chelator-phytosterol conjugates and contribute to the blockchain with information about the cardiovascular protection, anti-inflammation, and anti-systemic edema properties of phytosterol compounds, including medical cannabis phytosterols. In another example, authorized users of the distributed validated cannabis testing system can access and input information regarding the manufacture, distribution, supply, administration and use of compositions containing synthetic antagonists, such as taranabant, otenabant, and AM6538, as well as the inverse agonist/antagonist rimonabant.

In certain embodiments, a cannabis product received from any one or more of the sources described above can be subjected to a variety of testing protocols for research or public use that detect the quality and quantity of desired components and undesired components. A supplier, researcher, healthcare professional, or a consumer of one or more cannabis products can evaluate the origin, efficacy, potency, and quality of the one or more cannabis products by accessing information obtained from other actors in the supply chain or as obtained through a variety of testing protocols. Quantity of desired components and undesired components in a cannabis product can be expressed in terms of absolute weight, absolute volume, or relative weight or relative volume as compared to other components in the cannabis product. Testing protocols can include one or more analytical tests and methods of separation, identification, and quantification of the chemical components. For example without limitations, a cannabis product can be subjected to a battery of routine analytical tests or to a specialized research study. Testing protocols can include without any limitation, one or more of the following: microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, quality control, quality assurance, additional testing services, or combinations thereof. Analytical tests, for example without limitations, can include extractables/leachables studies, reference standard characterization, structural elucidation of target/lead compounds, structural elucidation of unknowns, impurity and degradation studies, identification and characterization of the quantity of chemical components, synthesis and purification of impurities and degradation products, and elemental analysis of the cannabis products. Analytical tests, for example without limitations, can include tests establishing the cannabinoid profile, and the efficacy and potency of the cannabinoids present, tests determining the dosage delivered by a particular formulation or food product, and tests for producing products with the appropriate dose. The cannabinoid profile includes the identification and quantification of at least the major cannabinoids found within a cannabis product. For example, in certain embodiments, determining the quantity of desired components in a cannabis product includes determining the concentration of one or more cannabinoids in the one or more cannabis products. For example, in certain embodiments, the quantity of desired components like tetrahydrocannabinol (THC) along with other cannabinoids and terpenoids can be determined by either liquid chromatography, mass spectrometry or both. This is especially important for edible forms of cannabis products, where a greater percentage of active ingredients reach the bloodstream. Appropriate dosage can bring about medicinal or health benefits to the consumer, while excess or improper dosage can have detrimental side effects.

As used herein, microbiological testing can include but is not limited to testing protocols that detect, for example, the presence of microorganisms, the type of micro-organisms, the quantity, or combinations thereof. Examples of microbiological testing include total plate count, aerobic plate count, anaerobic plate count, psychrotrophic plate count, probiotic, genomic, proteomic and multiomic testing. Examples of undesired microorganisms include, without limitations, E. coli, coliforms, lactic acid bacteria, mesophilic spore formers, mold, yeast, and thermophilic spore formers.

As used herein, food testing can include but is not limited to testing protocols for the food industry that detect the quality and quantity of desired components and undesired components, for example without limitations, the presence of microorganisms, the type of microorganisms, the quantity, or combinations thereof. Examples of food testing include total plate count, aerobic plate count, anaerobic plate count, psychrotrophic plate count, probiotic, genomic, proteomic and multiomic testing. Examples of undesired microorganisms include, without limitations, coliforms, E. coli, Salmonella, Staphylococcus aureus, and fungi like yeasts and molds.

As used herein, liquid testing can include but is not limited to testing protocols that test liquids containing cannabis products to detect the quality and quantity of desired components and undesired components. For example without limitations, a cannabis product in a liquid form can be tested for the presence of microorganisms, the type of microorganisms, the quantity, or combinations thereof. Examples of liquid testing include total plate count, aerobic plate count, anaerobic plate count, probiotic, genomic, proteomic and multiomic testing. Examples of undesired microorganisms include, without limitations, coliforms including fecal coliforms, E. coli, Salmonella, Staphylococcus aureus, and fungi like yeasts and molds. Certain embodiments of the disclosure include testing protocols for detecting the presence and quantity of pathogenic microorganisms, for example, without limitations, Bacillus cereus, Campylobacter, Chronobacter, Clostridium perfringens, Hemorrhagic E. coli (0157:H7), Listeria monocytogenes, Non-0157 STEC E. coli, Salmonella, Staphylococcus aureus, Shigella, Vibrio, and Yersinia.

In certain embodiments of the disclosure, a cannabis product received from any one or more of the sources described above can be subjected to a variety of testing protocols that determine compliance regulatory guidelines from federal and state agencies and boards, including, but not limited to, guidelines for labeling, packaging, compounding, administering to a patient, or marketing, or combinations thereof. For example, without limitations, federal agencies that regulate labeling of food products include the FDA and the USDA. Examples of regulatory guidelines also include, without limitations, guidelines regarding labeling, nutritional claims, monitoring and rating of cannabis products, or combinations thereof. Another embodiment of the disclosure, in consultation with one or more federal and state agencies or boards, is a method of establishing appropriate standards for cannabis products according to grade, condition, cannabinoid profile, THC concentration, or other qualitative and quantitative measurements deemed acceptable or compliant by the one or more federal and state agencies or boards.

In certain embodiments of the disclosure, a cannabis product received from any one or more of the sources described above can be subjected to a variety of testing protocols to determine compliance with cannabis product labeling guidelines from federal and state agencies and boards. For example, without limitations, federal agencies that regulate labeling of food products include the FDA and the USDA. Examples of labeling guidelines include, without limitations, guidelines for the nutrition facts panel, the ingredient statement and allergen declaration, the nutritional claims, the statement of identity, the net contents statement, the type size and placement requirements for the label, and combinations thereof. For example, packaging cannabis products for consumption as food must conform to rigorous requirements by federal and state agencies and boards. By utilizing certain embodiments of the disclosure, one can save time and avoid costly mistakes as a result of improperly labeled food products. By utilizing certain embodiments of the disclosure, a professional can review and provide direction, and guidance for compliance with regulatory guidelines. In another example, labeling guidelines include, without limitations, guidelines for human prescription drug and biological products, such as active components, possible adverse reactions and contraindications.

In certain embodiments of the disclosure, a cannabis product received from any one or more of the sources described above can be subjected to a variety of testing protocols to determine the appropriate labelling information and prepare labels or reports for compliance with cannabis product guidelines from federal and state agencies and boards. For example, without limitations, different cannabis products can be consumed in different ways like smoking, vaporizing, eating a food product, drinking a liquid product, or utilizing injectable, sublingual or topical formulations. Labeling cannabis products for each of these consumption modalities will require detailed testing regarding the quality and quantity of desired components and undesired components. Certain embodiments of the disclosure include methods and systems to display on cannabis products received from any one or more sources described above, a plurality of identification information associated with the cannabis products. For example, by utilizing certain embodiments of the disclosure, one can develop the appropriate label or report required for the labeling or packaging necessary to prepare cannabis products for consumption. Certain embodiments of the disclosure result in the production of an appropriate nutrition facts panel for a cannabis product, including without limitation, the appropriate format and the contents for the panel as required by the regulatory agency or board, like the chemical analysis, the calorific analysis, the ingredient analysis, and combinations thereof. Other identification information associated with the cannabis products include source of the cannabis products, the particular strains of the cannabis plant, and the quality and quantity of desired components in the cannabis product. Information on the label can also include the various diseases that can be treated or mitigated using the cannabis products, such as but not limited to depression, pain, nausea, headaches, insomnia, glaucoma, epileptic seizures, inflammatory bowel diseases, lupus, arthritis, Parkinson's disease, post-traumatic stress disorders, and muscle spasms. These diseases can be acute or chronic in nature. Information on the label can also include one or more beneficial effects associated with the use of cannabis products, such as relief from anxiety or pain, improvements in lung health, lessen side effects of other drug treatments, and increase the effectiveness of other drug treatments. In certain embodiments of the disclosure, a user can access a database of cannabis products and receive information regarding the cannabis products, the nutritional analysis, an efficacy profile, the source of the ingredients, and details regarding the producers, processors, and sales entities associated with the cannabis product.

Certain embodiments of the disclosure also include labeling of the cannabis products with one or more visual indicators associated with the quality and quantity of desired components in the cannabis products. Certain embodiments of the disclosure also include labeling of the cannabis products with one or more visual indicators associated with each of the specified ranges of quantity of desired components in the cannabis product. Concentration includes, for example, the amount of a particular chemical component as compared to all others from oils, and plants products. The concentrations may be expressed, for example, in one or more of the following ways: percentage of weight/weight; percentage of volume/weight; percentage of volume/volume; percentage of weight/volume; percentage of particular chemical component/total active pharmaceutical ingredients (API(s)); and percentage of API(s)/total chemical component(s). Embodiments of the disclosure can also be based on cannabis plant derived-components or based on cannabinoids in a product. For example, as shown in Table 1, an edible product made from the cannabis strain popularly called Pineapple Express contains moderate levels of tetrahydrocannabinol (THC) but low levels of cannabidiol (CBD) and cannabinol (CBN). For example, as shown in Table 2, a cannabis product intended for consumption as a vaporizer or smoke, like a cannabis concentrate made from the cannabis strain popularly called Purple Babba Kush contains high levels of tetrahydrocannabinol (THC) but low levels of cannabidiol (CBD) and cannabinol (CBN). Tables 1 and 2 are exemplary examples and in no way limit embodiments of the disclosure. Other components that can be analyzed and indicated on the labels of the cannabis products include but are not limited to tetrahydrocannabivain (THCV), cannabichromene (CBC), and cannabicyclol (CBL). Visual indicators can be bars, charts, graphs, symbols, codes or other graphical representations to indicate the relative concentration of one or more components in a cannabis product. Visual indicators can also indicate the efficacy or potency of the particular cannabis product to treat or mitigate particular illnesses or diseases. Embodiments of the disclosure can further include, for example, a reference standard calculated for each cannabis strain as understood by those skilled in the art and from there a percent (%) value from 0 to 50 percent can be assigned to each of the cannabis' API components. (With 0 being the lowest to 50 being the highest concentration % values, along with a moderate/medium concentration in the middle.) Embodiments of the disclosure allow consumers to make educated decisions regarding which products to consume or purchase based on the desired symptomatic relief or desired beneficial health effect.

TABLE 1 Major Components of Edible Cannabis Products from cannabis strain-Pineapple Express. Major Low Moderate High Components Concentration Concentration Concentration % THC 18% % CBD 0.19% % CBN <0.05% 

TABLE 2 Major Components of Edible Cannabis concentrates consumed through use of vaporizers. Major Low Moderate High Component Concentration Concentration Concentration % THC 26% % CBD  0.19% % CBN <0.05%

By way of example, an embodiment of the disclosure can include an online cannabis testing system or a home kit testing system. An embodiment of this system includes one or more indicators/processors, an input/output unit or apparatus adapted to be in communication with the one or more processors, one or more cannabis databases in communication with the one or more processors or stand-alone apparatus to store and associate a plurality of regulatory guidelines with a plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product, one or more electronic interfaces positioned to display an online user report or apparatus readout and defining one or more cannabis user interfaces; and non-transitory computer-readable medium positioned in communication with the one or more processors and having one or more computer programs stored thereon. The computer program includes a set of instructions that when executed by one or more processors cause the one or more processors to perform operations of generating the cannabis user interface to display to an user thereof one or more online cannabis user reports, the cannabis user interface allowing an input of a plurality of information associated with the user or with the cannabis product, determining whether the cannabis product meets the regulatory guide-lines responsive to receiving the plurality of information associated with the user or with the cannabis product and information from the one or more cannabis databases, associating the plurality of regulatory guidelines with the plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product, and outputting to the one or more cannabis user interfaces the one or more online cannabis user reports, the cannabis user reports including one or more of the plurality of information associated with the user or with the cannabis product, and one or more of the plurality of measurements of quality and quantity of desired components and undesired components in a cannabis product.

Certain embodiments of the disclosure integrate the testing results from cannabis processing centers with other information associated with the cannabis products and thereby address a public need for standardized information and regulation of legal cannabis products. Certain embodiments of the disclosure allow for tracking the identity, quality and quantity of raw materials, and the desired and undesired components in them, as the raw materials the cannabis plants are processed to finished cannabis products, packaged and labeled for wholesale and retail outlets. Certain embodiments of the disclosure allow for research or public use, federal agencies or state regulatory agencies to regulate consumption and provide further guidelines for testing and regulation as well as allow for consumers to be fully informed of the product they purchase or consume. Package labeling for regulation and accurate information requires the integration of several analytical testing to provide the data and information needed to appropriately certify a product. Certain embodiments of the disclosure provide governing agencies a way of monitoring and regulating legal distribution of cannabis products. By a way of example, an embodiment of the disclosure can include measuring the quality or quantity of THC (or other cannabinoids) in edible products and certifying or producing a label that indicates that that the tested product meets appropriate regulations such as having no more than 100 milligram of THC in an edible cannabis product.

In certain aspects, all testing protocols that detect the quality and quantity of desired components and undesired components in the cannabis products can be carried out in one or more cannabis processing centers for research purposes, public use purposes, or a combination thereof. These centers are equipped to receive samples of cannabis products from a plurality of users, subject the samples of cannabis products to the appropriate testing protocols, and deliver a plurality of information associated with the user or with the cannabis product. Testing protocols that can be housed in a cannabis processing center include without any limitation, one or more of the following: microbiological testing, food testing, acidified food testing, liquid testing, pathogen testing, additional testing services, or combinations thereof. Testing protocols for a cannabis product can be performed by one or more cannabis processing centers. For example without limitation, one cannabis processing center can perform a subset of the testing protocols like microbiological testing and pathogen testing, while another processing center can perform food and nutritional testing on the same samples. A cannabis processing center can be remote from or house the one or more cannabis databases that store a plurality of regulatory guidelines with a plurality of measurements of quality and quantity of desired components and undesired components in the cannabis products. A cannabis processing center can also be remote from or house the equipment and personnel required to perform the testing protocols to determine whether the cannabis products meet the regulatory guidelines. A cannabis processing center can also be remote from or house the equipment and personnel required to perform the testing protocols to determine the quality and quantity of desired components and undesired components in the cannabis products. The cannabis processing centers can be certified testing centers that comply with the guidelines and regulations from state or federal control boards or agencies including but not limited to the US Department of Agriculture, the Food and Drug Administration, and the Drug Enforcement Agency.

According to an exemplary embodiment of the disclosure, the cannabis processing center includes one or more labs that have good laboratory practices and current good manufacturing practices set by federal or state agencies as understood by those skilled in the art to performing quality testing and quality assurance procedures. Embodiments of the disclosure including analyzing cannabis and cannabinoid products for research studies to test and set parameters for third parties, such as government agencies, for grant awards, public safety, quality control and quality assurance purposes.

FIG. 1 is an illustration of an exemplary embodiment of the methods of the disclosure. In one embodiment, the method involves the use of cannabis testing procedures 101. In a further embodiment, the cannabis testing procedures can be housed in a cannabis processing center. Users of this embodiment of the disclosure submit samples of their cannabis products for testing. These cannabis testing procedures 101 detect the quality and quantity of desired components and undesired components in the cannabis products. Testing protocols include without any limitation, one or more of the following: microbiological testing, food testing, acidified food testing, liquid testing, pathogen testing, additional testing services, or combinations thereof. For example, users of cannabis smoking products 102 can submit their samples for quality control and quality assurance testing 103. In certain embodiments of the disclosure, users of cannabis pharmaceutical products 104 can submit their samples for quality control and quality assurance testing 103. In certain embodiments of the disclosure, users of cannabis food and beverage products 106 can submit their samples for quality control and quality assurance testing 107. In certain embodiments of the disclosure, users of cannabis medicinal or health products 105 can submit their samples for quality control and quality assurance testing 107.

In certain embodiments of the disclosure, users can access a variety of information, recommendations, and advisory reports 109 relating to labeling and regulatory compliance aspects of cannabis products submitted for testing. Users of certain embodiments of the disclosure can access a variety of information and reports 110, including, but not limited to, reports regarding the origin and processing records, the chemical and biological contents of the cannabis products submitted for testing. Certain embodiments of the disclosure include users like federal and state agencies or boards accessing the information to generate reports 108, including, but not limited to, reports regarding the various cannabis products available in the various industries, production and processing volumes of the various products, the producers of the various products, and their compliance to the laws and regulatory guidelines. Information from certain embodiments of the disclosure, like the database with all the product data, is important in helping producers, processors, and sellers sustain or improve their product and their performance in the supply chain, and for making decisions regarding which producers, processors, and sellers can be relied on to meet specified requirements of the consumers, or the appropriate regulatory agencies or boards. In certain embodiments of the disclosure, a cannabis product received from any one or more of the sources described above can be subjected to a variety of testing protocols to help federal and state agencies and boards with conducting safety assessments and recalls of the cannabis products, and other enforcement actions.

FIG. 2 is an illustration of an exemplary embodiment of the methods of the disclosure. Samples are submitted by users 201 for quality control testing, quality assurance testing, or both quality assurance and quality control testing. In certain embodiments of the disclosure, these samples can be initially processed 203 for the appropriate testing procedures 202. In other embodiments of the disclosure, the samples can be directly utilized in any of the testing procedures 202 that detect the quality and quantity of desired components and undesired components. Testing protocols include without any limitation, one or more of the following: microbial testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, additional testing services, or combinations thereof. In certain embodiments of the disclosure, these samples are subjected to microbial testing 204 that detect, for example without limitations, the presence of microorganisms, the type of micro-organisms, the quantity, or combinations thereof.

In certain embodiments of the disclosure, these samples are subjected to analytical testing procedures 205 that detect the quality and quantity of desired components and undesired components. Analytical tests, for example without limitations, can include extractables/leachables studies, reference standard characterization, structural elucidation of target/lead compounds, structural elucidation of unknowns, impurity and degradation studies, identification and characterization of the quantity of chemical components, synthesis and purification of impurities and degradation products, and elemental analysis of the cannabis products.

In certain embodiments of the disclosure, these samples are subjected to quality control tests 206. Quality control testing ensures that cannabis products of a high quality, good safety profile and with the desired potency are supplied to the public, for their good health and for the economic benefits derived from trade of safe cannabis products. In certain embodiments of the disclosure, the samples subjected to quality control tests range from the raw materials to finished products. In certain embodiments of the disclosure, testing can be conducted to ensure that products at each step of the cannabis product supply chain meet quality and safety standards specified by the appropriate regulatory agencies or boards.

In certain embodiments of the disclosure, these samples are subjected to quality assurance tests 207. Quality assurance is a comprehensive program designed to ensure that one or more of the cultivation, production, processing, or sales of the cannabis products, or combinations thereof, meet a minimum standard of quality. In certain embodiments of the disclosure, this quality assurance ensures that the products from a particular producer, processor or seller meet the minimum standards set by the regulatory agencies or boards. In certain embodiments of the disclosure, this quality assurance ensures that the products from a particular producer, processor or seller meet the appropriate standards set by the regulatory agencies or boards. In certain embodiments of the disclosure, this quality assurance ensures that the products from a particular producer, processor or seller are consistent with the labeling on the product.

In certain embodiments of the disclosure, these samples are analyzed for their compliance with labeling and other regulatory guidelines 208. In certain embodiments of the disclosure, cannabis products are analyzed for compliance with guidelines for the nutrition facts panel, the ingredient statement and allergen declaration, the nutritional claims, the statement of identity, the net contents statement, the type size and placement requirements for the label, and combinations thereof.

In certain embodiments of the disclosure, users can access a variety of information, records, recommendations, and advisory reports, collectively described as user reports 209, resulting from the testing of the cannabis products. Users of certain embodiments of the disclosure can access a variety of information and reports 209, including, but not limited to, reports regarding the origin and processing records and the chemical and biological contents of the cannabis products submitted for testing. Certain embodiments of the disclosure include users like federal and state agencies or boards accessing the information to generate reports 209, including, but not limited to, reports regarding the various cannabis products available in the various industries, production and processing volumes of the various products, the producers of the various products, and their compliance to the laws and regulatory guidelines.

Certain embodiments of the disclosure involve the systems, computer-readable program product, and related computer-implemented methods to obtain information from the users and generate cannabis user reports, according to embodiments of the present disclosure as discussed above. These embodiments can be implemented using one or more computers, one or more servers, one or more databases, and one or more cloud computing configurations, and one or more communications networks. Certain embodiments of the disclosure include a system for collecting a plurality of information related to a cannabis product and maintaining a registry. The plurality of information includes but is not limited to information regarding cannabis production facilities, cannabis strains, cannabis products, associated test results and compliance certificates, cannabis processing and distribution systems, and ultimate consumers. The plurality of information can also include information from inventory tracking software, like Colorado's Marijuana Inventory Tracking Solution (MITS).

Certain embodiments of the disclosure include a system with one or more remote electronic interfaces configured to receive selection parameters entered by user and display a plurality of information related to one or more cannabis products. The system also has one or more databases that acquire and store the plurality of information related to one or more cannabis products and one or more processors in communication with the one or more databases. These processors are configured to acquire selection parameters entered by user through remote electronic interfaces, generate a data package from the plurality of information related to the cannabis product in the database responsive to the selection parameters entered by user and display the data package to the user responsive to the selection parameters entered by user through remote electronic interfaces.

Embodiments of the disclosure can include, for example, analyzing one or more cannabis products to determine the quality and quantity of desired components and undesired components in the one or more cannabis products using one or more of the following, for example: cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, quality control testing, quality assurance testing, or combinations thereof. Embodiments can further include, for example, determining concentration of one or more cannabinoids and determining the appropriate regulations for the cannabis products such as the relevant state regulations regarding the sale or consumption of cannabis products. Embodiments of the disclosure can further include comparing measurements of the quality and quantity of desired components and undesired components in the one or more cannabis products against state regulations for consumption of the one or more cannabis products and generating a report, for example that includes if the cannabis product satisfied the appropriate regulations.

FIG. 3 is an illustration of a system that is an exemplary embodiment of the disclosure. Such a system can include, for example, a communications network 310, a plurality of electronic interfaces 320, cannabis testing computer system 300, associated interfaces 302, associated servers 301, and a database 330. One or more entities can operate or control the cannabis testing computer system 300 that includes associated interfaces 302 and associated servers 301, with communication to a database 330, and a plurality of electronic interfaces 320. The communications network 310 can include a telephony network, a wireline network, a wireless network, a wide area network, a local area network, an infrared network, a radio-frequency network, an optical network, or any cloud computing configurations, or any other communications network now or hereinafter created as is known and understood by those skilled in the art. Each of the plurality of electronic interfaces 320 allows a human user, such as a producer, a processor, or a consumer, to interact with the cannabis testing computer system 300. Each of the electronic interfaces 320 allows such a human user, for example, to input information associated to one or more cannabis products as is described herein with respect to the cannabis testing system. Each of the electronic interfaces 320 allows such a human user, for example, to receive the cannabis user reports, and to access appropriate information from the cannabis testing system.

The reports from the cannabis testing system may be received by a user in a variety of formats, including, but not limited to, paper printouts, graphical or text displays on a computer or mobile device, electronic messages like an e-mail or text, and other equivalent formats. The output from a cannabis testing system can include other techniques including updating a record in a database, updating a spreadsheet, and sending instructions and/or data to specialized software, such as an application on a mobile device, or combinations thereof. In other embodiments, the output from a cannabis testing system may include formats and reports stored on computer readable medium (such as a CD, DVD, USB flash drive, stand alone, or other removable storage device, computer hard drive, or computer network server, etc.). The output from a cannabis testing system, particularly those stored on computer readable medium, can be part of a database, which may optionally be accessible via the internet, such as a database of information regarding various cannabis products, the associated producers, processors or sellers stored on a computer network server. The database may be a secure database with security features that limit access to information regarding various cannabis products, such as to allow only authorized users to view them.

According to various exemplary embodiments of the present disclosure, the database 330 can be any database structure as is known and understood by those skilled in the art. The databases discussed herein, including database 330, can be, for example, any sort of organized collection of data in digital form. Databases, including database 330, can include the database structure as well as the computer programs that provide database services to other computer programs or computers, as defined by the client-server model, and any computer dedicated to running such computer programs (i.e., a database server). An exemplary database model, for example, is a Microsoft SQL Server 2014 CTP2 or SQL Server 2012, or SQL Server 2008 R2. Databases can include a database management system (DBMS) consisting of software that operates the database, provides storage, access, security, backup and other facilities. DBMS can support multiple query languages, including, for example, SQL, XQuery, OQL, LINQ, JDOQL, and JPAQL. Databases can implement any known database model or database models, including, for example, a relational model, a hierarchical model, a network model, or an object-oriented model. The DBMS can include Data Definition Language (DDL) for defining the structure of the database, Data Control Language (DCL) for defining security/access controls, and Data Manipulation Language (DML) for querying and updating data. The DBMS can further include interface drivers, which are code libraries that provide methods to prepare statements, execute statements, fetch results, etc. Examples of interface drivers include ODBC, JDBC, MySQL/PHP, FireBird/Python. DBMS can further include a SQL engine to interpret and execute the DDL, DCL, and DML statements, which includes a compiler, optimizer, and executor. DBMS can further include a transaction engine to ensure that multiple SQL statements either succeed or fail as a group, according to application dictates. DBMS can further include a relational engine to implement relational objects such as Table, Index, and Referential integrity constraints. DBMS can further include a storage engine to store and retrieve data from secondary storage, as well as managing transaction commit and rollback, backup and recovery, etc.

Data stored in fields of the databases can be updated as needed, for example, by a user with administrative access to the database to add new data to the libraries in the database as they become supported. It will be appreciated by those having skill in the art that data described herein as being stored in the databases can also be stored or maintained in non-transitory memory and accessed among subroutines, functions, modules, objects, program products, or processes, for example, according to objects and/or variables of such subroutines, functions, modules, objects, program products or processes. Any of the fields of the records, tables, libraries, and so on of the database can be multi-dimensional structures resembling an array or matrix and can include values or references to other fields, records, tables, or libraries. Any of the foregoing fields can contain either actual values or a link, a join, a reference, or a pointer to other local or remote sources for such values.

Database 330 can be, for example, a single database, multiple databases, or a virtual database, including data from multiple sources, for example, servers on the World Wide Web. The cannabis database 330 can contain several types of data, including, but not limited to, plant information associated with the cannabis products, growth information of the plants, environmental information, plant management information, raw material processing information, cannabis product distribution information, and results from testing cannabis products. These results from testing cannabis products can include, without limitations, chemical composition, additive information, microorganism information, cannabinoid profile, nutritional information, and market information. In certain embodiments of the disclosure, the market information can include historical sales data, sales projection data, and real-time market values for raw materials and processed cannabis products in a variety of industries. The plant information associated with the one or more cannabis products in the one or more cannabis databases includes one or more of: cannabis strain, source of seeds, genotype and phenotype of the plants associated with the one or more of the cannabis products, and combinations thereof. The environmental information associated with the one or more cannabis products in the one or more cannabis databases includes one or more of: germination conditions, location, temperature, water, exposure to light, and combinations thereof. The plant management information associated with the one or more cannabis products in the one or more cannabis databases includes one or more of: pesticide use, fertilizer use, growth pattern control, and combinations thereof. The consumer information associated with the one or more cannabis products in the one or more cannabis databases includes purchase patterns, disease indication, diagnostic test results, dose, dosage, time frame of administration, prescribing healthcare professional's data, adverse reaction reports, contraindication report, and therapeutic efficacy. Database 330 can be the inventors' proprietary database or one populated with data from publicly available databases or a combination thereof.

According to various exemplary embodiments of the present disclosure, for example, and as illustrated by FIG. 3, the cannabis database 330 can be part of a data warehouse. Such a data warehouse may include other databases, for example, a user database, an administration database, content from or links to other public databases, a regulatory guidelines database, and/or a sales database. The user database can be configured, for example, to store any data related to user information, including user names, user addresses, state or federal authorization information, payment records, data related to user's products or consumption needs, and any other information related to a user, as is known and understood by those skilled in the art.

Embodiments include a system for managing the cannabis product from seed to treatment outcome. As shown in FIG. 4, the system has a general flow through modules that represent stages of information management. The first is the seed module 410 where profiling and characterization of the seed takes place. This characterization includes genetics and multiomics to provide a fingerprint for the cannabis product(s) that is/are generated. The seed module 410 is vital for traceability and reproducibility of cannabis products. The second module is the agriculture module 420 where monitoring/profiling occurs through IT integration with agricultural tools for data collection and tracking. There are tools for monitoring outside plots (typically 0.5 to 1 acre plot), or indoor cultivation, that monitors agricultural parameters that include temperature, humidity, pressure, along with seed, soil and plant markers for profiling and detailing the growth and development of the cannabis product. The next module is the product testing module 430 where either the crop or product is processed and tested. The product testing module 430 provides lab solutions management that include one of more analytic techniques like liquid chromatography or gas chromatography (LC/GC), analysis software, data management and enhanced security feature for testing crop/product and determining if product is safe for release to patients. The next module is the product release module 440 where a product has been certified and labeled appropriately and reports generated that characterizes the product and its correlation to the seed from whence it came. The product release module 440 manages reports for distributors, pharmacists, physicians, regulators and other pertinent personnel. The system continues with a patient administration module 450 that includes pharmaceutical formulation, compounding, kits, packaging and imaging conjugation. The patient administration module 450 will be vital to manage prior for appropriately guiding the next treatment outcome module 460. The next module is the treatment outcome module 460 where administration of the cannabis product to a patient is monitored and treatment outcome is validated. The treatment outcome module 460 involves pharmacists, physicians and patients with data management integration that utilizes Federal and State regulated guidelines for patient health information to monitor and determine treatment outcomes. The treatment outcome module 460 will also provide researchers with both validation information and new information to guide the next steps in translational research. In some embodiments, the seed module 410, the agriculture module 420, the product testing module 430, the product release module 440, the patient administration module 450, and the treatment outcome module 460 can be arranged in any order.

Each module provides information to a given product that allows for correlating any given step with the other processes associated with that given product. These modules are managed by information integration across a blockchain system to provide the overall comprehensive data for providing any cannabis product. In some embodiments, data collected in each module can be uploaded to a blockchain identifier (BCI) unit 400. As a result, each module can download and share data from other modules that were uploaded to the BCI unit 400. In addition, data uploaded to the BCI unit 400 from individual modules can be uploaded to a cloud server 470. In other embodiments, data collected in each module can be uploaded directly to the cloud server 470. In some embodiments, the BCI unit 400 and the cloud based server 470 are integrated to a single unit.

Embodiments include systems and methods of supplying a cannabis product through a blockchain platform. The systems and methods include tracking and testing the seed, the planting, the crop, the product, the treatment and the distribution for ensuring quality control and quality assurance for a safe product for human administration. In some embodiments, data collected from each module are uploaded to the BCI unit 400 and/or the cloud server 470, where the BCI unit 400 and/or the cloud server 470 can generate a unique BCI in a certain predetermined period. The BCI can include a blockchain that an individual block further includes timestamps and hash values. The BCI can include a block that includes all data uploaded by each module. The block may also include a current hash value which is generated from the data uploaded by each module in the current predetermined period. The block may also include a past hash value of a previous block generated immediately before the current predetermined period. This way, the past hash value serves as a link (hence the term “chain”) between the previous block and the current block, forming a blockchain. Each block or the entire blockchain included in the BCI can be downloaded by each module. This way, each module can download a reduced sized block or blockchain than downloading the entire data uploaded to the BCI unit 400 and/or the cloud server 470.

The seed module 410 includes systems and methods for acquiring data of a seed. The systems and methods include obtaining a seed from a source and profiling that seed. Profiling includes genetic sequencing and multiomic analysis to determine properties of a given strain producing a data set. The source and the data set generated from profiling can be uploaded to the BCI unit 400 to generate a unique BCI. The source and the data set generated from profiling can be uploaded to a cloud server 470 associated with the assigned BCI.

Several characteristics and properties of medical cannabis begin with the seed and its profile. Embodiments include determining the genetic sequence of the cannabis seed to characterize a given strain. An approved grower will submit seeds for genetic analysis and further characterization, such as multiomic analysis. The genetic profile is used as an identifiable marker for the given development of a particular crop of cannabis plants. Once the seed is characterized by its genetic profile, it is then assigned a unique identification code that is used subsequently for accessing and verifying purchases and transfers associated with that seed and its progeny.

In certain embodiments of the disclosure, a seed profile can contain information that includes genetic sequence, germination, genetic purity, protein and enzyme markers, genotyping, phenotyping, hybridization, genus and species determination to name a few. Profiling may further include plant tissue residue analysis, genetically modified events detection, seed treatment applications detection, seed stability and storability, seed quality assurance development, seed plantability assessment and seedling growth rates. The profile information is obtained from seed testing and/or an existing seed bank that has characterized the seed. Comparative testing can be performed on seeds with seed bank profiles in order to reconcile if there are differences in sequences that have not been previously characterized. Genetic strain determination is associated with seed profiling to allow for predicting, determining, characterizing and comparing cannabinoid product profile.

In certain embodiments of the disclosure, information associated with a variety of cannabis seeds is received from a breeder or a seed bank. Information regarding seeds corresponding to a single strain and a specific breeder or seed bank can be stored as a seed record on a blockchain-based transaction platform. Embodiments include a method of purchasing seeds of a specific strain of cannabis. The method includes the steps of receiving a request for seeds from a grower for a particular strain of cannabis or for seeds that would yield a particular cannabis product profile. Information regarding the growers can be stored as grower records on the blockchain-based transaction platform. In the next step, a particular seed record is identified in response to the request by comparing the request to the seed records stored on the blockchain-based transaction platform, and information from this seed record for satisfying the request is conveyed to the trusted grower. If the trusted grower wishes to proceed with a financial transaction to purchase seeds corresponding to the matched seed record, then he can proceed with a purchase. Any financial transaction between the trusted grower and breeder is stored as a purchase record on the blockchain-based transaction platform and connected to the seed record, grower record, and breeder or seed bank record. Embodiments of the system also allow trusted parties to redact information from the blockchain-based transaction platform, without causing the transaction platform to fail for its intended purpose. Embodiments include the ability to match and identify the appropriate strain that is stored in system. A grower may request from a breeder a particular strain of cannabis seed. The breeder can then validate the profile of the seed from the record generated from the profile that is stored in blockchain-based platform.

The agriculture module 420 includes systems and methods of acquiring plant management data for a particular crop cohort. An embodiment of the method would include manually inputting planting parameters data and/or collecting planting parameters data with a sensor. Planting data include soil moisture, air moisture, water added or irrigated, climate control or fluctuation, barometric pressure, light source, nutrients, and pesticides. Embodiments include systems that include devices configured to sense soil and weather parameters and generate soil and weather records. An example of a device includes a containment unit with detection sensors that detect soil data and planting parameters data. Sensors that send data to containment unit can be attached to agricultural tools for directly measuring the plants for needed parameters. Soil parameters include moisture consistency, nutrients content, microorganisms, and toxicants. Soil analysis is performed periodically from planting to harvest. The soil data and planting parameters data can be uploaded to the BCI unit 400 to generate a unique BCI related to the particular cannabis strain, the grower, the location, and other growth parameters. The soil data and planting parameters can be uploaded to cloud server 470 associated with the assigned BCI.

Many factors affect the outcome of crop growth and development that may enhance or impede cannabis production, particularly factors associated with the planting and farming process. Embodiments of methods and systems include sensors that detect soil moisture, air moisture, water received by the plants, climate control or fluctuation, barometric pressure, light source, nutrients, and pesticides. The planting of the seed data is dated and time stamped and manually inputted and uploaded to the blockchain record established for the strain of seeds planted. Initial parameters are also inputted such as addition of nutrients, amount of water, or soil analysis. Subsequently sensors are placed to detect and capture the day to day factors that facilitate seed germination and growth. With each detection, the data is uploaded to the BCI unit 400 and/or the cloud server 470.

A salient feature to the propagation of cannabis plants is the root to soil interface. The soil provides crucial nutrients and moisture necessary to maintain the steady progress to a fully bloomed plant. Likewise, the soil contains a microflora that has substantial interaction with the plant's roots that helps to direct growth. This region of the soil is known as the rhizosphere. Embodiments include identifying the profile of the soil, including moisture consistency, nutrients, microorganisms, pesticides and toxicants. The soil analysis can be accomplished by microorganism test analysis and the data inputted to the BCI unit 400 and/or the cloud server 470. Subsequently sensors are placed to detect day to day soil changes where each detection generates data that is uploaded to the BCI unit 400 and/or the cloud server 470.

In certain embodiments of the disclosure, the agriculture module 420 includes sensors that directly measure agricultural parameters for monitoring and tracking the growth and development of the plant. Tools and devices used in the agriculture module 420 can be IT-integrated such that the sensors can directly send the data to a blockchain-based platform, thus allowing monitoring and tracking during harvesting, processing and storing prior to lab testing.

Growing of cannabis plants can occur in both outdoor environments such as arable land or indoor setting. In many cases, indoor platform-based systems has been developed to enhance the ability to control planting parameters for consistency and to improve harvest baring outcomes. Furthermore asexual propagation using cloning is also being developed for consistent plant production. Embodiments of the disclosure include sensors capturing climate and environment factors for either outdoor planting or indoor planting. The sensors would capture the day to day climate and environmental controls or changes, which would generate data that is uploaded to the BCI unit 400 and/or to the cloud server 470. In certain embodiments of the disclosure, the agriculture module 420 includes growth analytics, which relate to the correlation and grouping of the profile of a given seed or product.

Cannabis plants are often profiled and categorized with simplified descriptions indicating the psychoactive effects of THC, however comprehensive profiling of cannabis plants is much more extensive and correlation to growth analytics is an important part of this analysis. The disclosure includes embodiments of correlating the growth analytics to the cannabinoid profile outcomes of cannabis plants.

The sensors include a modular unit with probes that measure various desired parameters, for example a probe that explicitly measure barometric pressure. The modular unit integrates with platform directly sending the data to blockchain-based platform. For outdoor plant operations, weather services are integrated for weather prediction and monitoring to further maintain record of anomalies or changes due to abhorrent or favorable weather patterns. The platform allows for manual input of information, where comparison of measured data can reconcile discrepancies. The overall agricultural module 420 provides for establishing data to be uploaded to a BCI unit 400 and/or to the cloud server 470 for stepwise tracking and monitoring from the agricultural process to human consumption. After the cannabis plants are harvested, the plants are processed to an end product. Depending on the use of the plants, the product can prepared to meet the medical, research, or recreational markets.

The product testing module 430 include systems and methods for comprehensive product testing, as disclosed in U.S. Pat. No. 9,632,069, is incorporated here by reference in its entirety. Data generated from the product testing module 430 can be uploaded to the BCI unit 400 to generate a unique BCI. The data generated from the product testing module 430 can be uploaded to a cloud server 470 associated with the assigned BCI.

Determining whether a cannabinoid product is safe for administration or consumption is one of the main purposes of an integrated comprehensive testing module, as it is the last line of defense prior to direct human administration. Safety profile, quality control, and quality assurance will be key to releasing a product for administration. Embodiments include a blockchain platform that includes blocks containing information from certain series of tests. Tests include microbiology/pathogens/mycotoxins, pesticides/toxicants, residual solvents/liquids, heavy metals, terpene profiling, and cannabinoid potency. The sequence of testing has priority, particularly when determining the whether a medical cannabinoid product is safe for human consumption. The system may use a pass or fail system based on standardization of allowed levels of substances. There are industry and governmental agency thresholds for desired and undesired components in foods and drugs that are not permissible for human consumption.

Embodiments include systems and methods of testing cannabis crop or product through a series of analytical testing including testing for microbes, pathogens and/or mycotoxins, toxicants, residual solvents and liquids, heavy metals, and the cannabinoid content and potency. An example method includes creating data records corresponding to results from the analytical testing. Data records can be uploaded to the BCI unit 400 to generate a unique BCI assigned to the particular cannabis strain, the grower, the location, and other growth parameters. The data records can be uploaded to a cloud server 470 associated with the assigned BCI.

Embodiments include systems and methods of microbial, pathogen, and toxin analysis of a cannabis crop or product. An example method includes the steps of analyzing a prepared sample of the cannabis products for microbiological, pathogenic and mycotoxin content, determining whether the sample is safe to continue with other testing. Safety parameters are set based on guidelines according to the Botanical Drug Development-Guidance for Industry outlined in FDA-CDER in December 2016 Pharmaceutical Quality/CMC Revision 1. At any stage of analysis, if the sample is deemed unsafe, then further analysis can be halted. If the sample is deemed safe, then further analysis is conducted. The data generated from the analysis is subsequently uploaded to the BCI unit 400 to generate a unique BCI assigned to the particular cannabis strain and trusted growers. The data records can be uploaded to a cloud server 470 associated with the assigned BCI.

FIG. 5 shows an example sequence for the product testing module 430. In block 502, a sample with an assigned BCI is prepared. The sample can be transported to a testing location and prepared for the various testing modalities. For example, in block 504, the sample is weighed in a moisture sensitive balance to measure moisture content. Knowing moisture content provides the ability to determine if the sample is prone to growing mold, and the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. In block 506, the sample is tested for microbes/pathogens/mycotoxins. For example, the testing can be administered by LC/MS and in a biosafety hood, and the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. Samples are placed in a biosafety hood to determine microbial/pathogen growth. This step is very critical in the process in as much as a sample failing to have a safe microbiological/pathogenic/mycotoxin profile would immediately not continue with the rest of the series of testing. In block 508, if the sample fails to have a safe microbiological/pathogenic/mycotoxin profile, further testing is halted. This arrest in the testing series is conducted for two reasons: 1) the product is not safe for consumption and/or 2) the sample can contaminate the rest of the testing system. In block 510, if the sample has a safe microbiological/pathogenic/mycotoxin profile, the sample undergoes further testing for pesticides and toxicants. The testing can be administered by LC/MS; at which the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. In block 512, the sample undergoes testing for residual solvents. The testing can be administered by GC/MS, where solvents used for extraction, synthesis or preparation may be within the content of the product; at which the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. In block 514, the sample undergoes testing heavy metal content. The testing can be administered by ICP, and the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. In block 516, the sample undergoes terpene profiling. The terpene profiling can be administered by GC-QP to determine other components beyond cannabinoid products that may be in the product; at which the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. In block 518, the sample undergoes cannabinoid profiling for components and potency. The cannabinoid profiling can be administered by HPLC; at which the data generated in this step can be uploaded to the BCI unit 400 and/or the cloud server 470 to generate a unique BCI. While the embodiment described in FIG. 5 provides for generation of a unique BCI identifier at every step, other embodiments include generation of an identifier that builds on the preceding steps. Other embodiments include generation of an identifier at every step that captures the identifiers of the preceding steps.

Block 510 includes systems and methods for performing a toxicant analysis of a cannabis product. An example method may include preparing a sample of a cannabis product for analysis of toxicant content. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI assigned to a record identifying the cannabis strain. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI. Block 512 includes systems and methods for residual solvent and liquid analysis of a cannabis crop or product. An example method may include analyzing a prepared sample of the solvent and liquid content. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI. Block 514 includes systems and methods for heavy metal analysis of a cannabis crop or product. An example method may include analyzing a prepared sample of the heavy metal content. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI. Block 516 includes systems and methods for terpene profile and analysis of a cannabis crop or product. An example method may include analyzing a prepared sample of the terpene content. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI. Block 518 includes systems and methods for cannabinoid analysis of a cannabis crop or product. An example method can include analyzing a prepared sample for the cannabinoid content and potency. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI. Once the sample undergoes a series of testing, the product is determined whether it is safe for release to patients. If the sample is determined safe, the product can be released to patients, as shown for example via the product release module 440, as shown in FIGS. 4 and 5. Products from this representative sample is now certified and can be labeled as such on packaging from the party providing the product. Optionally, in block 520, the product can be stored over a period of three months to a year, or longer periods as desired. The shelf life of the product can be determined in this step. After the storage period, a sample from the stored product can be obtained and resubmitted to undergo the entire sequence of testing.

Block 520 includes systems and methods for testing the shelf life of a cannabis crop or product. An example method may include storing a sample for a desired period of time and testing for microbes, pathogens and/or mycotoxins; testing for pesticides and toxicants; testing for residual solvents and liquids; testing for heavy metals; analyzing the terpene profile; and testing the cannabinoid content and potency. At each testing step the data produced from testing can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. At each testing step the data produced from testing can be uploaded to a cloud server 470 associated with the assigned BCI.

Referring back to FIG. 4, the product release module 440 includes systems and methods for releasing a safe product. Once the sample is determined safe in the product testing module 430, the product can be released to patients. Products that pass the product testing module 430 is now certified and can be labeled as such on packaging from the party providing the product. Reports can be generated that characterizes the product and its correlation to the seed from whence it came.

In certain embodiments of the disclosure, the product release module 440 includes distributing the certified product to distributors, pharmacies, clinics, and hospitals. The product can be distributed to recreational retail stores. The product release module 440 manages reports for distributors, pharmacists, physicians, regulators and other pertinent personnel. Data produced from the product release module 440 can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data produced from the product release module 440 can be uploaded to a cloud server 470 associated with the assigned BCI.

The patient administration module 450 includes systems and methods for administering the released product to the patient. In certain embodiments of the disclosure, the patient administration module 450 includes administering the certified product to the patient. Data produced from the patient administration module 450 can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product. The data produced from the patient administration module 450 can be uploaded to a cloud server 470 associated with the assigned BCI.

In certain embodiments of the disclosure, depending on the purpose of the product, a conjugate can be added to the product for imaging purposes. The conjugate is configured to chelate radioisotopes to the product for imaging. The product including the conjugate is administered to the patient and radioisotopic imaging is conducted. The imaging results can be used to validate the outcome of the treatment in the treatment outcome module 460.

Embodiments include systems and methods for administering and imaging a radiolabeled conjugated cannabis active pharmaceutical ingredient (API). An example method includes conjugating the cannabis API for administration with a cyclam derivative, radiolabeling the conjugated cannabis API, administering to a patient the radiolabeled conjugated cannabis API, and imaging the administered radiolabeled conjugated cannabis API through various imaging modalities. The imaging modalities include PET, SPECT, CT, MM, Ultrasound or a combination thereof. Data generated from the analysis can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product and associated with the given patient. The data generated from the analysis can be uploaded to a cloud server 470 associated with the assigned BCI.

The treatment outcome module 460 includes systems and methods for monitoring the administration of the cannabis product to a patient and validating the treatment outcome. Data produced from the treatment outcome module 460 can be uploaded to the BCI unit 400 to generate a unique BCI associated with the given strain that produced the crop or product and associated with the given patient. The data produced from the treatment outcome module 460 can be uploaded to a cloud server 470 associated with the assigned BCI.

Embodiments of the disclosure include collecting data from clinical outcomes post-cannabinoid product administration. Many factors surround the administration of the cannabinoid product that are required for determination and correlation of treatment outcomes. One of the first parameters are patient data, which includes but not limited to, genetic profiling, multiomics profiling, known disease pathologies, current drug intake, demographic factors and environmental factors. Each patient is has a unique set of factors that impact treatment outcomes. Having access to the comprehensive validated data from seed to patient will allow for treatment outcomes to be appropriately correlated to an individual patient. The data for the patient is uploaded to the BCI unit 400 and/or the cloud server 470 that is HIPPA compliant. One of the salient features this blockchain method provides is a means of monitoring treatment efficacy through imaging modalities. The medical cannabis API is conjugated to cyclam derivative that allows for various imaging tracers to chelate to the composition and image the biodistribution of the medical cannabis API. Coupling the imaging modality provides a real-time method of determining if the medical cannabis uptake is occurring in the appropriate tissue regions or whether elimination of the product occurs. Advantageously, coupling the imaging modality can determine whether an improper CBD is administered or whether an adjustment of the dosage is necessary. If so, the physician may alter the administration. This treatment outcome information is uploaded to the BCI unit 400 and/or the cloud server 470 for the patient and correlated to the BCI of the strain that was collected.

Embodiments include systems and methods for profiling a patient. An example method includes acquiring and inputting certain patient data. Patient profile data includes but not limited to genetic profiling, multiomics profiling, known disease pathologies, current drug intake, blood analysis, urine analysis, demographic factors, and environmental factors. Patient profile data can be uploaded to the BCI unit 400 to generate a unique BCI associated for the given patient compliance with Federal and State guidelines such as HIPPA guidelines. The patient profile data can be uploaded to a cloud server 470 associated with the assigned BCI.

Embodiments of the disclosure allow for the true correlation of patient data, patient modes of administration, and clinical outcomes of cannabis administration to be validated through monitoring cannabinoid uptake by imaging, in both the research setting and clinical setting. Treatment outcomes are not limited to human patients, but other animal subjects (in vivo and ex vivo) as well as in vitro assays. The conjugated cannabinoid provides a useful platform to explore cannabinoid products in a way that was not previously available. The connection of treatment outcome to seed and patient provides a holistic and tailored method of delivering medicine to a subject. The integrated information analytics can direct therapy, research, and safety profiles in both a patient centric format as well as a patient population format. This platform utilizes a precision medical approach to investigate and validate the connectivity of agricultural life science to product development and distribution and ultimately with human consumption and healthcare.

Embodiments of the disclosure include means of bridging product to patient centric treatment. In an embodiment, patient data from electronic medical records (EMR) systems is deidentified and supplied to the distributed validated cannabis system and this data includes medical review of patient profile and response to product administration. The EMR devices connect screening data with imaging data that validates patient response to administration. Devices provide access to the BCI information for a given product to know where the entire process that brought the cannabis product up to the point of administration and further connect that data with the patient's treatment outcome.

Data generated at every step of the method require processing, analysis and storage. Embodiments includes cloud based systems 470 for uploading and storing data generated at each step of the process with an association to a BCI. In certain embodiments of the disclosure, a computer implemented method for storing data on a cloud server 470 is disclosed. The cloud server 470 receives a request from a user or device to store data on the server. The cloud server 470 also receives from the user or device the BCI associated with that data. The server then determines processing and analysis based on preset algorithms for correlations. The server has the flexibility to allow for inputted algorithms for determining correlations. In some embodiments, the BCI unit 400 and the cloud server 470 are integrated to a single unit.

Embodiments include systems and methods for accessing, activating, bringing up the data associated with the BCI by an end user with predefined settings, and/or recording of the identity of an end user for any electronic device or computing device that is used by one or more users. The end user approaches an electronic device that can access the cloud server 470, the electronic device prompts the user for manual input of authentication, identification data and/or BCI, upon manually entering said authentication and or identification data into the electronic device, the authentication and or identification data is verified by the electronic device, then data transmitted to the electronic device from the cloud server 470. End users include, but not limited to the government, distributors, physicians, patients, pharmacists, growers, and researchers.

Embodiments include systems and methods for automating the accessing, activating, bringing up blockchain data associated with a BCI with end user predefined settings. An example system includes an electronic device, computing device, or non-transient medium including an electronic interface. The electronic interface communicates wirelessly with various electronic devices, and passes on the information to and from the electronic devices on a display. The display is part of the electronic device or is operatively connected to the electronic device to be accessed. The electronic device prompts the user to enter the password, display successful or unsuccessful login, and includes a memory controller that stores user information whereby the user is prompted on the display to enter a password if the information passed on from the electronic interface indicates that the user is an authorized user. The password is checked for validity and if valid the password is sent to the electronic interface for transmission and storage in the cloud server 470. The user is automatically allowed access to the electronic device and/or the predefined settings for that user is automatically loaded to the electronic device if the information passed on from the electronic interface indicates that the user has entered a valid password.

A key component to the integration process is the transmittal of data from devices to a cloud server 470 along with data being transmitted between devices and an interface to any given user. Embodiments of the disclosure include Internet of Things (IoT) for connecting multiple devices for capturing, transmitting, processing, analyzing, and storing data. The transmitted data is associated with a BCI for tracking and categorizing the data that is accessed at any interface. The process as described in FIG. 4 accentuates different access points of data collecting that may represent multiple devices sending data to the blockchain ledger for a given BCI. Information cannot be altered from the immutable ledger in the blockchain system, but only verified and validated. Security provision will be established that allows the appropriate entity to access the data or report needed.

Embodiments include a distributed validated system for managing the cannabis product from seed to treatment outcome. FIG. 6 is a schematic representation of blocks created to manage information related to a cannabis product across a distributed validated system. Block 602 is created that contains the genetic profile of a seed used for production of a cannabis product. Block 602 is linked to block 604. Block 604 contains plant growth conditions of a crop used for production of the cannabis product and allows access to the information in the block 602. Block 604 is linked to block 606. Block 606 contains manufacturing information for production of the cannabis product and allows access to the information in the blocks 602 and 604. Block 606 is linked to block 608 and block 610. Block 608 contains storage information with regards to the cannabis product and allows access to the information in the blocks 602, 604, and 606. Block 608 is linked to block 610. This block 610 contains information from the testing of the cannabis product to determine quality and quantity of desired components and undesired components in the cannabis product using one or more of: cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, quality control testing, quality assurance testing, or any combinations of the foregoing. This block 610 also contains information about the concentration of one or more cannabinoids in the cannabis product. Block 610 allows access to the information in the blocks 602, 604, 606, and optionally 608. Block 610 is linked to block 612. Block 612 contains information about the cannabis product satisfying the appropriate regulations for consumption of the cannabis product, and allows access to the information in the blocks 602, 604, 606, 610, and optionally 608. Block 612 is linked to three blocks 614, 616, and 618. Block 614 contains information about the disposal of cannabis product that does not satisfy the appropriate regulations for consumption of the cannabis product, and allows access to the information in the blocks 602, 604, 606, 610, 612, and optionally 608. Block 616 contains information about the offer for sale and sale of the cannabis product as a consumer consumption product, and allows access to the information in the blocks 602, 604, 606, 610, 612, and optionally 608. Block 618 contains information about the use or administration of the cannabis product by a healthcare professional, such as dose and dosage of the cannabis product provided to a patient. Block 618 allows access to the information in the blocks 602, 604, 606, 610, 612, 620, and optionally 608. Block 620 is also linked to block 618, and contains information about the patient to whom the cannabis product is administered, such as presenting symptoms, diagnosis, and other personal health information. Block 618 is linked to block 622. Block 622 contains treatment outcome information about the patient to whom the cannabis product is administered and allows access to the information in the blocks 602, 604, 606, 610, 612, 618, 620, and optionally 608.

In an example embodiment, the disclosure provides a method of managing information related to a cannabis product across a distributed validated system. The method includes enabling a first authorized user to create a first plurality of data containing genetic profile of a seed used for production of a cannabis product. The method includes associating the first plurality of data to a first record which is identified by a first unique identifier. The method includes storing the first record into a memory for access by one or more of a plurality of authorized users using the first unique identifier. The method includes enabling a second authorized user to create a second plurality of data containing plant growth conditions of a crop used for production of the cannabis product. The method includes associating the second plurality of data to a second record which is identified by a second unique identifier. The method includes storing the second record into the memory for access by the one or more of the plurality of authorized users using the second unique identifier, wherein the second unique identifier provides access to the first plurality of data and the second plurality of data. The method includes enabling a third authorized user to create a third plurality of data containing manufacturing information for production of the cannabis product. The method includes associating the third plurality of data to a third record which is identified by a third unique identifier. The method includes storing the third record into the memory for access by the one or more of the plurality of authorized users using the third unique identifier, wherein the third unique identifier provides access to the first plurality of data, the second plurality of data, and the third plurality of data. The method includes analyzing the cannabis product to determine quality and quantity of desired components and undesired components in the cannabis product using one or more of: cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, liquid testing, pathogen testing, quality control testing, and quality assurance testing. The method includes determining concentration of one or more cannabinoids in the cannabis product. The method includes enabling a fourth authorized user to create a fourth plurality of data containing measurements of the quality and quantity of desired components and undesired components in the cannabis product. The method includes associating the fourth plurality of data to a fourth record which is identified by a fourth unique identifier. The method includes storing the fourth record into the memory for access by the one or more of the plurality of authorized users using the fourth unique identifier, wherein the fourth unique identifier provides access to the first plurality of data, the second plurality of data, the third plurality of data, and the fourth plurality of data.

This disclosure provides for the generation and use of novel agents for precision medicine. Embodiments include compositions that provide a theranostics approach targeting the endocannabinoid system (ECS) implicated in the pathogenesis of neurologic disorders and cancer. This individualized medicine platform allows to deliver personalized medicine designed on the basis of individual genetic make-up, biochemistry, molecular imaging, molecular blueprint, and clinical observations and measurements associated to each patient's disease.

Embodiments described here include novel compositions and methods of using these compositions for imaging or treatment of diseased cells. Certain embodiments include compositions containing a cannabinoid analog and a chemotherapeutic agent. Certain embodiments include compositions containing a chemotherapeutic agent and a cannabinoid analog conjugated to a chelator. In certain embodiments, the chelator is cyclam. In certain embodiments, the cannabinoid analog is a cannabidiol. Certain embodiments include compositions containing a combination of a chemotherapeutic agent and a cannabinoid analog conjugated to a chelator and a label. In certain embodiments, the chemotherapeutic agent is Bruton's tyrosine kinase inhibitors, such as ibrutinib (IBN) and zanubrutinib (BGB). In certain embodiments, the chemotherapeutic agent is a proteasome inhibitor, such as carfilzomib (CFZ). In certain embodiments, the chemotherapeutic agent is tumorex (TMX).

Embodiments described here include novel compositions and methods of using these compositions for imaging diseased cells. These methods can be applied in the diagnosis, assessment, and treatment of any medical disorder with pharmaceuticals, medical cannabinoids, and combinations thereof. The diseases may include various forms of neurologic disorders and cancer. In particular, cancer can include one or more carcinoid, neuroendocrine cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head and neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, colorectal cancer, and cancers of hematopoietic origin such as lymphoma, or leukemia. The neurologic diseases can include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis, posttraumatic stress disorder (PTSD), epilepsy, seizures, Tourette's syndrome, schizophrenia, anxiety disorders, autism, depression, dementia, and other diseases and disorders that implicate the nervous system.

These methods have benefits to enhance existing imaging modalities that may include improvement in sensitivity and specificity, improvement of patient convenience, and reduction of adverse effects, time and costs. These methods for imaging diseased cells or a group of cells at a site of a diseased tissue or organ of a subject will enable health professionals to diagnose a subject, especially when that subject is being treated or under treatment with medical cannabinoids. Certain embodiments include methods of imaging at the site of a disease in a given subject to perform a pre- or post-treatment evaluation and to be able to monitor that subject for as long as that subject is being treated or under treatment with medical cannabinoids. In certain aspects, the method comprises detecting a signal generated by an imaging agent-labeled chelator-medical cannabinoid analog composition at the site of the disease of a subject, where the diseased cells, if present, generate a more intense signal than the cells in the surrounding tissue.

As used herein, the term “subject” refers to all kinds of animals including humans, rodents, other mammals, or avian species. The administration of the imaging agent-labeled chelator-medical cannabinoid analog conjugates can serve as a diagnostic agent, a prognostic agent, or an agent to alleviate or treat a disease in a subject. The target site can be any tissue of the subject, including but not limited to the brain, heart, lung, esophagus, intestine, breast, uterus, ovary, prostate, testis, stomach, bladder, or liver. Also, embodiments provided herein can be used as agents to target diseases, such as cancer or neurologic, gastrointestinal, metabolic, and neuroendocrine disorders. As used herein, the term “administration” refers to an activity of introducing a composition described herein to a subject by an appropriate method, and the composition may be administered via various routes of intravenous, oral, intramuscular, transdermal, intra-peritoneal, topical, sublingual, buccal, inhalation, nasal, or ophthalmic routes as long as they can deliver the same to the target tissues. The compositions described herein can be delivered as pharmaceutical formulation. A ‘pharmaceutical formulation” refers to a mixture of one or more of the compounds described herein, or a pharmaceutically acceptable derivative as an active ingredient, and at least one pharmaceutically acceptable carrier or excipient. The purpose of a pharmaceutical composition is to facilitate administration of a compound to a subject. In another aspect, a pharmaceutical composition can contain a compound of one of the formulae described herein, or a pharmaceutically acceptable derivative, and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition includes two or more pharmaceutically acceptable salts, acids, esters, excipients, carriers, diluents, and combinations thereof.

The term ‘pharmaceutically acceptable derivative” as used herein refers to and includes any pharmaceutically acceptable salt, pro-drug, metabolite, ester, ether, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, upon administration to a subject, is capable of providing (directly or indirectly) the active ingredient. For example, the term “a pharmaceutically acceptable derivative” of compounds described herein includes all derivatives of the compounds described herein (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, and adducts) which, upon administration to a subject, are capable of providing (directly or indirectly) the compounds described herein.

As used herein, the term ‘pharmaceutically acceptable salt” refers to those salts, which retain the biological effectiveness and properties of the parent compound. And unless otherwise indicated, a pharmaceutically acceptable salt includes salts of acidic or basic groups, which may be present in the compounds of the formulae disclosed herein. The present disclosure also provides certain processes, as examples, for the preparation of the above pharmaceutically acceptable salts, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and pharmaceutical compositions containing them.

Certain embodiments relate to pharmaceutically acceptable salts formed by the compounds described herein, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenylsubstituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, beta-hydroxybutyrate, chloride, cinnamate, citrate, formate, fumarate, glycolate, heptanoate, lactate, maleate, hydroxymaleate, malonate, mesylate, nitrate, oxalate, phthalate, phosphate, monohydro genphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propionate, phenylpropionate, salicylate, succinate, sulfate, bisulfate, pyrosulfate, sulfite, bi sulfite, sulfonate, benzenesulfonate, p-bromophenyl sulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.

Certain embodiments include novel methods to synthesize agents that are conjugates of a chelator and a targeting ligand. Such agents may be used for imaging, diagnostic and/or therapeutic purposes. Accordingly, an embodiment includes a method of synthesizing a chelator-targeting ligand conjugate containing N4 and medical cannabinoid analogs. The method can further include synthesis with a metal in the form of an organometallic or a photon source. In some aspects, the metal ion is a radionuclide as described here.

Embodiments also include kits to prepare an imaging probe, a diagnostic agent, or a pharmaceutical composition. Certain specific embodiments include methods of imaging, diagnosing, or delivering a pharmaceutical composition to treat physiological disorders with medical cannabinoids. Accordingly, in an embodiment, any imaging modality can be used to detect signals from the one or more labels. Non-limiting examples of imaging methods used to detect the signals from the labels include PET, PET/CT, CT, SPECT, SPECT/CT, MM, near-infrared (NIR), optical imaging, optoacoustic imaging, and ultrasound. Methods described here can be used to assess the personalized and efficacious dose and dosing regimens based on accurate evaluations determined through molecular imaging using medical cannabinoids.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include phytocannabinoids that are naturally occurring plant-derived cannabinoids. The active components in the medical marijuana strains Cannabis sativa and Cannabis indica are medical cannabinoids, which include more than 60 analog types, and two additional classes of bioactive molecules known as flavonoids and terpenoids, which are all naturally occurring compounds that are extracted and isolated from plants. Embodiments of the compositions that function as theranostics agents also include label-chelator-terpenoid analog conjugates, label-chelator-flavonoid conjugates, and label-chelator-phytosterol conjugates. Among the natural medical phytocannabinoids, Δ⁹-tetrahydrocannabinol (A⁹-THC), cannabidiol (CBD), and cannabinol (CBN) are the most abundant, yet other phytocannabinoids can play a very important role in precision medicine. Based on structure, binding properties and signaling/function features, medical cannabinoids are grouped into distinct classes: (i) the classical medical cannabinoids, which consist of both natural plant extracts such as A⁹-THC and chemically synthesized compounds such as Marinol; (ii) Nonclassical medical cannabinoids, mainly exemplified by the synthetic cannabinoid receptor (CB) agonist CP-55,940; (iii) Aminoalkylindoles, which consist of chemically produced cannabinoids like AM1241; (iv) Diarylopyrazoles, mainly comprise CB inverse agonists (or antagonists) such as SR141716A, also known as rimonabant; and (v) endogenous endocannabinoids, which are naturally produced by animal and human cells and include N-arachidonoylethanolamine, (AEA) or anandamide, 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine and N-arachidonylodopamine (NADA).

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include the medical cannabinoids that have been approved for clinical research worldwide, as dronabinol, nabilone, nabiximols, cannador, cannabidiol, cannabinol, cannabigerol, tetrahydrocannabivarin, and cannabichromene. Embodiments of the label-chelator-medical cannabinoid analog conjugate can include medical cannabinoids such as HU-210, A⁹-THC, A⁸-THC and desacetyl-L-nantradol, which are recognized as CB1/CB2 receptor agonists, without distinctive specificity for either receptor. A⁹-THC stands out as a C. sativa cannabinoid, which exhibits CB1/CB2 affinity and the highest psychotropic effects. By a pentyl substitution on A-THC side chain, conversion into the HU-210 analog occurs, with increased receptor affinity. Other structural modifications of the THC backbone lead to new and selective CB2 agonists JWH-133, JWH-139, and HU-308 and L-759633 and L-759656, which display affinities at the nanomolar range.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include non-classical medical cannabinoids, which are a family of bicyclic (AC) and tricyclic ACD medical cannabinoids. They are prominently represented by CP55940, along with CP55244 and CP47497 analogs. Of note, CP55940 is the best-known medical cannabinoid agonist, which displays a potent in vivo effect via shared CBi and CB₂ signaling.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include aminoalkylindoles. R-(+)-WIN55212 is the prototype of this family with medical cannabinoid-like features, which can bind both CBi and CB₂ receptors but exhibits higher specificity for CB₂ and can mimic in vivo THC-mediated effects. Other analogs like JWH-015 and L-768242 also show similar CB₂ affinity as R-(+)-WIN55212.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include medical diarylpyrazoles, which are a class of medical cannabinoid analogs whose distinctive function is to inhibit CBi or CB₂-dependent intracellular signaling pathways, acting as antagonists (inverse agonist); for example, embodiments can include SR141716A, AM251 and AM281 that inhibit CBi receptor mediated effects.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can include certain endocannabinoids. N-arachidonoylethanolamine (AEA), or Anandamide, is an example of an eicosanoid that is converted into its active form, via the omega-3 (co-3) and omega-6 (co-6) biosynthetic fatty acid pathways, and specifically targets CB receptors in mammals. Consequently other eicosanoids that can function in these embodiments include methanandamide (R and S isomers), arachidonyl-2-chloroethylamide (ACE A), arachidonylcyclopropylamide (ACPA) and 2-arachidonoylglycerol (2-AG), which exhibit binding affinity to CBi and CB₂.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can be used as theranostic agents targeting serious pathologies, such as cardiovascular, neurological, psychiatric, immunological, endocrine and neoplastic disorders. For instance, specific formulations of cannabinoid compounds are able to reduce proliferation and induce tumor cell death. Moreover, the mechanisms behind the anti-proliferative cell-killing effects (up to 70%) are known to result from intracellular signals driven by the binding of the cannabinoid agents to specific GPCRs, CBi and CB₂ of the ECS.

The ECS facilitates rapid local response to pathologic states or diseases. For example, when signals resulting from increased activation of neuronal Ca²⁺ channels or cellular stress cascades are transduced, immediate biosynthetic conversion of membrane phospholipids ensues, which leads to production and secretion of anandamide. Then, the endocannabinoid transmitters bind and activate target CB receptors, which in turn modulate adenylyl cyclase catalytic function to homeostasis and reduce cyclic adenosine monophosphate (cAMP) levels and protein kinase A activity, thus achieving equilibrium of Ca′ fluxes and simultaneously correcting potassium (K⁺) channels. Upon completion of their regulatory function, Anandamide and or 2-AG undergo physiological degradation via the Fatty Acid Acyl Hydrolase (FAAH) activity or analog enzymatic pathways. Notably, the ECS also has the capacity to regulate the levels of its target CBi or CB₂ receptors, particularly in response to cell stress signaling. This function could be interpreted as a positive feedback mechanism to modulate the degree of signal transmission in certain pathologic states such as neuropathic pain and multiple sclerosis. The ECS system works conversely in disorders, such liver fibrosis or colorectal carcinoma. In the former, CBi levels are upregulated and thus signaling could result in deleterious progression toward cirrhosis of the liver, whereas in the latter, the low CBi expression will impinge upon analgesic benefits. On the other hand, endo and exo medical cannabinoids crosstalk with the opioid, serotonin, and N-methyl-d-aspartate (NMDA) nociceptive (pain) circuitry networks.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can be used to evaluate the impact of medical cannabinoids in health and disease and to determine the early success or failure for specific applications. The label can be used to monitor the effect of the specific medical cannabinoid analog in the management of chronic pain. This can be achieved by imaging the medullary periaqueductal grey and rostral ventromedial areas to monitor analgesic effects. Additionally, one can take advantage of specific medical cannabinoid analogs targeting CB₂ that are selectively expressed by sensory neurons at the dorsal root ganglion, the spinal cord, and brain regions, to study and monitor the mechanisms of medical cannabinoid-driven analgesia.

Embodiments of the label-chelator-medical cannabinoid analog conjugate can be used to dissect and better understand the ECS and other pathways that modulate parallel functions aimed at protecting and maintaining a subject's homeostasis. CBi is mainly expressed in central and peripheral nervous system but discrete distribution has been observed in other tissues. Thus, utilization of the label-chelator-medical cannabinoid analog conjugates directed to CBi signaling can result in broad and pleiotropic actions. Although the CB i receptor has been known to primarily regulate functions associated to cognition, memory, perception, mood, behavior and psychotropic activities, there is increasing evidence that it can play a role in analgesia; cardiovascular, respiratory, and reproductive functions; as well in the maintenance of overall homeostasis. CB₂ receptors are predominantly expressed in immune competent organs where cells undergo antigen-dependent maturation and selection programs, which empowers them to survey and mount powerful responses against pathogens and aberrantly developed cells. CB₂ exhibits a relatively limited distribution in the central nervous system (CNS). CB₂-dependent activation involves regulatory mechanisms that support immune cell migration to the site of inflammation and the release cytokines. The expression of CB₂ is particularly important for CNS microglia, as demonstrated by the capacity of medical cannabinoid agents to reduce cytokine-mediated neuro-inflammation. Embodiments of the label-chelator-medical cannabinoid analog conjugate that include specific CB₂ ligands, such as 0-3223 (a synthetic CB₂ specific agonist), can be used for anti-inflammatory and anti-nociceptive applications, without apparent CBi-like mediated effects.

This disclosure also provides for innovative radiopharmaceutical imaging analogs that can be used to diagnose, stage, restage and treat central nervous, cardiovascular and cancer diseases. Imaging with radiolabeled physiological agents can be implemented using nuclear molecular agents, which provide accurate measurements of molecular pathways, by integrating real-time nuclear imaging protocols. This approach is designed to enhance clinical capability for patient selection, improve pharmacokinetic assessments, optimize dosage formulations and predict therapy outcomes. The overall impact of the comprehensive application of theranostics (diagnosis/therapy/prognosis) technology to medical cannabis platforms, stems from the evolving versatility of nuclear imaging analogues and the emerging competence of hybrid instrumentations, which will provide precision, sensitivity, specificity and real-time data tailored to individual patient's diagnosis and therapy.

Compositions containing the label-chelator-terpenoid conjugates can be used to study, monitor, and provide the potent antioxidant, anti-inflammatory, analgesic, anticancer, antibiotic and anti-psychiatric (anxiety and depression) benefits of terpenoid compounds.

Compositions containing the label-chelator-flavonoid conjugates can be used to study, monitor, and provide the antioxidant, anti-inflammatory and anticancer properties of flavonoid compounds, including polyphenol cannabis flavonoids. The cannabis flavonoids can provide significant cardiovascular protection, particularly improving coronary and peripheral circulation by maintenance of homeostatic blood pressure, prevention of the formation of blood clots, and reduction of atherosclerosis risks. Mechanisms of cannabis flavonoids mediated antioxidative and anti-inflammatory effects include apigenin (4′,5,7-trihydroxyflavone)-dependent inhibition of TNF-α, which has also shown to exhibit therapeutic benefits in multiple sclerosis and rheumatoid arthritis.

Compositions containing the label-chelator-phytosterol conjugates can be used to study, monitor, and provide the cardiovascular protection, anti-inflammation, and anti-systemic edema properties of phytosterol compounds, including medical cannabis phytosterols.

Embodiments of the label-chelator-medical cannabinoid conjugate can utilize tetra-azacyclic (N4) conjugation-based technology, also known as N4-technology, which can also be adapted for serial multi-imaging/therapy of a subject. Here, the hydrophobic chelator(s)-based N4-technology coordinates metals to form a complex that may be conjugated to hydrophobic/hydrophilic molecules, including medical cannabinoid analogs to produce novel compounds or to better understand the bio-distribution scope and targeting capabilities of exiting compounds. N4 conjugation of novel or existing compounds can be used for purposes including imaging, cold therapy, and radiotherapy that targets specific cell receptors, pathways, tissues or organs, using medical cannabinoids. Moreover, certain N4 compounds may be obtained from other commercial sources, which are noted in U.S. Pat. No. 8,758,723. In addition, metal isotopes are either obtained from generators such as ^(99m)Tc, ¹⁸⁸Re and ⁶⁸Ga, or from commercial sources such as ⁶⁴Cu and ¹¹In, which are available and cost-effective. N4-conjugates provide a simple platform for small molecules, peptides, or antibodies with high purity and efficient formulation to target components of the endocannabinoid system. Moreover, radiolabeled N4-conjugates provide molecular target assessment in the areas of abnormal cell cycle and epigenetic microenvironments. Similarly, N-4 theranostic applications offer post-treatment evaluation and can be tailored for internal radio-therapeutics, when the conjugate is labeled with ¹⁸⁸Re or ¹⁷⁷Lu (beta and gamma emitters) or ²²⁵Ac, ²²³Ra (alpha emitters) for simultaneous SEE and TREAT approaches. Moreover, the N4 technology provides the flexibility to prepare conjugates with or without cold platinum metals, thus enabling the N4 chemistry to increase the cold payload of medical cannabinoids to optimal concentrations for cellular and immunotherapy as theranostics agents. The radiolabeled N4-conjugates are focused on the imaging of immuno-modulatory functions and the therapy of oncological and neurological diseases, via cannabinoid receptor/transporter-mediated mechanisms. This medical cannabinoid precision-based technology platform integrates diagnostic imaging (molecular imaging) with innovative tools to understand the dynamic changes in pathway-activated cell receptors leading to tissue degeneration, inflammatory, and proliferative disorders to improve patient diagnosis, therapy and prognosis. This technology allows for the medical cannabinoids to be utilized as a therapeutic for treatments amenable to cannabinoids alone or as combinations with radiopharmaceuticals, immunopharmaceuticals, and other compounds.

Several synthetic antagonists taranabant, otenabant, and AM6538, as well as the inverse agonist/antagonist rimonabant show great promises as therapeutic agents. For example, in targeting obesity, rimonabant showed to promote weight loss, weight maintenance and to prevent weight regain in patients with a BMI of greater than 27 kg/m², when accompanied with at least one risk factor such as hypertension or type 2 diabetes. However, rimonabant had increased frequencies of psychiatric adverse events, including major depression, dysthymia, seizures and suicide. These adverse effects discouraged its development as an approved therapeutic intervention for other disease states. While the cause of the adverse events has been speculated to result from the inverse agonist mechanism of the CB i receptor activity, many factors have not been considered where this technology platform could resolve other medical conditions. Likewise, agonists like the natural medical cannabinoid THC, have demonstrated great promise for therapeutic intervention. For example, medical THC has demonstrated benefits with refractory nausea and vomiting for patients undergoing chemotherapy along with alleviating neuropathic pain and spasticity. However, medical THC is psychoactive, which can also lead to lethargy, postural hypotension and decreased motor coordination when overdosing occurs. Conversely, given to the right patient, disease, and dose, it is conceivable that the effects against a disease by pathology biomarker-guided N4-THC theranostic imaging, can actually result in favorable clinical outcomes.

Combinations containing the label-chelator-medical cannabinoid analog conjugates combine imaging with the therapeutic intervention and can image in real time the uptake and activity of N4 conjugated medical cannabinoids, which is essential to select the individual patient with the targeted dysfunctional pathway (right disease) and to assess optimal dosage (right dose). This approach allows for visually seeing the composition located at the tissue site and determining the actual dose of uptake to that site for that patient. This platform allows one to evaluate: (a) if dosing is the cause of the adverse event; (b) if bioavailability is the cause or (c) if there is a limited uptake and/or bio-distribution. In keeping with these parameters, the embodiments serve to dissect effects that are patient dependent, particularly if one of these effects are genetic, epigenetic, or exhibit allelic variations associated to the individual's ECS.

The effective amount of a compound is determined based on several factors, such as age and weight of the patient, severity of the disease, other co-existing factors. The effective amount of a compound includes exemplary dosage amounts for an adult human of from about 0.1 to 100 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.

Furthermore, some medical cannabinoids have not yet been explored and this platform lays a foundation for conjugating several medical cannabinoids for investigating the effects in diverse physiological disorders, through a precision medicine approach. The N4 technology can allow for determination of the effectiveness in targeting, uptake and distribution; wherein the conjugates are imaged further allowing for the assessment of efficacy. Embodiments include the pharmaceutical formulation, kit preparation, and method of use and administration of pathway-directed molecular agents for non-metal/metal labeling and metallic/cold therapeutics, when such agents are prepared in aqueous or organic conditions. Synthesis and purification in organic solvents requires the use of protecting and de-protecting chemicals to achieve desired compositions.

Embodiments also include kits containing components to prepare an imaging probe that has a conjugate of a label, a chelator, and a cannabinoid analog. Embodiments also include kits containing components to prepare a diagnostic agent based on a conjugate of a label, a chelator, and a cannabinoid analog. Kits can also be constructed to contain components to deliver effective amounts of pharmaceutical compositions containing a conjugate of a label, a chelator, and a cannabinoid analog. Certain embodiments include kits for diagnostic imaging of a site of neurologic disorders and cancers, and delivery of a dual therapeutic intervention agent to a subject. The conjugate of the chelator and the cannabinoid analog can be present in the kit as precursors that subsequently interact with the imaging agent, when provided with suitable reaction conditions. For example, a kit can include one or more sealed containers contain a predetermined quantity of a chelator-medical cannabinoid analog conjugate and one or more sealed containers that contain a predetermined quantity of a second imaging agent that can be applied in imaging the brain of a subject. In some embodiments, the kit further includes a sealed container containing a radionuclide. In certain embodiments, a kit further includes a predetermined quantity of a chelator-medical cannabinoid analog conjugate and a sufficient amount of a reducing agent to label the conjugate compound with a radionuclide metal ion. In certain embodiments, a kit further includes a predetermined quantity of a chelator-medical cannabinoid analog conjugate and a reducing agent along with a buffer solution, wherein the reducing agent includes, but not limited to, tin(II) chloride. The kit may also contain other components, such as pharmaceutically acceptable salts, buffers, antioxidants, and preservatives. In certain embodiments, buffer solutions are phosphate buffer solutions to stabilize the chelator-medical cannabinoid analog conjugates. Phosphate buffer solutions may contain monosodium phosphate, disodium phosphate, or combination thereof, dissolved in water. In certain embodiments, an antioxidant is included in the chelator-medical cannabinoid analog conjugate composition to prevent oxidation of the chelator moiety. In certain embodiments, the antioxidant is vitamin C (ascorbic acid). Other antioxidants that can be used to include tocopherol, pyridoxine, thiamine, butylated hydroxyl toluene, sodium edetate, or rutin. In certain embodiments, a stabilizer is included in the chelator-medical cannabinoid analog conjugate composition to prevent degradation and to enhance shelf life or storage life of the chelator moiety. In certain embodiments, the stabilizer is mannitol. However, other components, such as sugars or bulking agents, may also be used, wherein the sugars are simple sugars, complex chain sugars, sugar alcohols or salts thereof. Stabilizers may include but are not limited to glucose, lactose, maltose, xylose, sorbitol, cellulose, or carboxymethylcellulose sodium. In certain embodiments the predetermined quantity of a chelator-medical cannabinoid analog conjugate may be present in dosing amounts to treat a neurologic disorder or cancer as a therapeutic intervention. The kit may contain the components in liquid, frozen, dry form, or lyophilized form.

EXAMPLES Example 1

Synthesis of 1,4,8,11-Tetraazacyclotetradecane-1′-propyl-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (also known as VYR207).

VYR207 can be synthesized in several ways. Shown below is Scheme 1 for the synthesis of 1,4,8-Tris(trifluoroacetyl)-1,4,8,11-tetraazacyclotetradecane (N4-TFA3; TFA3-cyclam).

Cyclam (N4;1,4,8,11-tetraazacyclotetradecane; N4; 7.53 g, 37.58 mmol) was dissolved in 30 mL of methanol. To this clear solution, NEt₃ (5.20 mL, 37.58 mmol) was added in one portion. Then, ethyl trifluoroacetate (18.0 mL, 150.3 mmol) was added dropwise over a period of 5 minutes while stirring. The homogeneous reaction mixture was cooled with ice-water bath to control the mild exothermic reaction and stirred at 25° C. under the atmosphere of N2 for 5 h. Volatiles were then removed under vacuum. The residue was dissolved in minimum amount of CH₂Cl₂ (2.0 mL) and passed through a short silica gel pad (25 g), eluted with 100% EtOAc. The eluent was concentrated to give the product a white semi solid form (17.1 g, 92.5%). The resulting compound was analyzed by proton nuclear magnetic resonance ¹H NMR), carbon-13 nuclear magnetic resonance (¹³C NMR), and high-resolution mass spectrometry (HRMS) by electrospray ionization (ESI). The ¹H NMR data, ¹³C NMR data, and the HRMS-ESI determination of mass of VYR207 are as follows.

The ¹H NMR data (200 MHz, CDCl₃): δ 3.85-3.25 (multiplet, 12H), 2.80 (broad singlet, 2H), 2.74-2.50 (broad singlet, 2H), 2.30-1.90 (multiplet, 2H), 1.85-1.63 (multiplet, 2H), 1.25-0.60 (multiplet, 1H), and the ¹³C NMR data (75.5 MHz, CDCl3): δ 158.74-157.31 (multiplet, C=0, multiplets due to existence of conformers), 122.84-11.32 (quartet, CF3, due to C—F coupling, Jc-_(F)˜264 Hz, further split due to existence of conformers), 51.2-46.2 (multiplet, CH₂ next to N), 29.4-27.8 (multiplet, CH₂); The HRMS-ESI mass calculated for Ci₆H₂iF₉N₄0 3 was C, 39.35; H, 4.33; N, 11.47; 0 9.83; and the mass found was: C, 39.19; H, 4.36; N, 11.33; O, 10.04.

Shown below is Scheme 2: Synthesis of Bromopropyl 4N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (Step 1 in Scheme 21.

N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716, rimonabant; 3.70 g, 7.57 mmol) was added to a magnetically stirred anhydrous CH3CN (30 mL). The mixture was stirred at room temperature until a solution was obtained (˜10 min). To this solution, K₂C03 (1.57 g, 11.43 mmol) and 1,3-dibromopropane (2.29 g, 11.35 mmol) were then added. The mixture was refluxed under the atmosphere of N2 for 16 h. The progress of the reaction was monitored by TLC (1:1 EtOAc/Hexane). The mixture was cooled to room temperature and filtered through a sintered glass filter to remove insoluble salt (washed with 20 mL CH3CN). The solvent was then concentrated to give yellow oil (6.3 g, 70%). Structure of starting material SR141716 was determined by NMR (FIG. 7) and HPLC (FIG. 8). As shown in the Table 3, the peaks and retention times show elution of SR141716 at peak 6 (7.994 minutes) with significant purity, as evidenced by the area % being greater that 99% for that data point.

TABLE 3 Retention Time Area Rank (minutes) (mAUs) Area % 1 5.570 6.55957 0.0804 2 7.331 5.72351 0.0702 3 7.588 3.46697 0.0425 4 7.682 0/91644 0.1204 5 7.824 5.12544 0.0628 6 7.994 8113.12109 99.4709 7 8.491 2.70567 0.0332 8 8.690 9.76111 0.1197

Conditions for HPLC were as set forth below. An Athena C18 column with particle size of 3 micrometer (μιη) and physical dimensions of 2.1 millimeter (mm) diameter and 100 mm length. The two solvents used were 0.1% phosphoric acid in 100% acetonitrile (Solvent A) and 0.1% phosphoric acid in 100% acetonitrile (Solvent B). The two solvents were utilized to create a gradient as shown in Table 4. The HPLC system was operated at a flowrate of 0.5 milliliters per minute (mL/min) and detection at 210 nanometers (nm).

TABLE 4 Time Solvent A Solvent B (in minutes) (Percent) (Percent) 0 0 100 2 0 100 7 95 5 10 95 5 10 Stop Stop

This compound SR141716 was then subject to conjugation and deprotection to yield 1,4,8,11-Tetraazacyclotetradecane-1′-propyl 4N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro phenyl)-4-methyl-1H-pyrazole-3-carboxamide (VYR207) (Steps 2-3 in Scheme 2).

A mixture of bromopropyl-[N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (4.4 g, 7.57 mmol) in anhydrous CH3CN (20 mL) was magnetically stirred at room temperature. To the reaction mixture, KOH powder (g, 11.35 mmol) and TFA3-cyclam (11.35 mmol) were added and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated on a rotary evaporator under reduced pressure. The residue was purified by flash chromatography using Hexane:EtOAc (6:4) as an eluent to afford TFA3-cyclam-conjugate as a white solid (16 g, 45%). To a solution of the TFA3-cyclam-conjugate (3.0 g, 3.05 mmol) in MeOH (6.0 mL) K2CO3 (1.26 g, 9.1 mmol) was added in one portion. The suspension was heated under reflux for 3 h. Toluene (30 mL) was then added to the cooled mixture. MeOH was removed by forming an azeotrope with toluene. After MeOH solvent was completely removed, the hot toluene suspension with inorganic salt was filtered and concentrated to give a desired free base (6.2 g, 86%) as a white solid.

Example 2

Synthesis of 1,4,8,11-tetraazacyclotetradecane-1′-acetyl [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (VYR206).

The structure of target compound VYR206 (aliphatic chain with carbonyl group) shown as Formula II and complete synthesis of VYR206 is shown in Scheme 3.

VYR206 can be synthesized in several ways. Shown below is a representative scheme, Scheme 3.

Step 1 in Scheme 3: Synthesis of 1′-Ethylacetyl [N-(Piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide]

N-(Piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; SR141716; 200 mg, 0.43 mmol) was added to a magnetically stirred anhydrous CH3CN (10 mL). The mixture was stirred at room temperature until a solution was obtained (10 min). To this solution, K2CO3 (200 mg, 1.44 mmol) and bromo ethylacetate (400 mg, 2.4 mmol) were then added. The mixture was refluxed under the atmosphere of N2 for 48 h. TLC (CHiCh/MeOH, 100:7) was used to monitor the reaction progress, which was completed after 4-8 hours. The mixture was cooled to room temperature and filtered through a sintered glass filter to remove insoluble salt (washed twice with 20 mL CH3CN). The residue was then isolated by column chromatography and eluted with methylene chloride followed by methylene chloride/methanol (100:6) to yield the desire compound as a white powder (428 mg, 55%).

Step 2 in Scheme 3: Synthesis of 1′-Acetic acid-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide]

The deesterification of ethylacetyled compound from step 1 was carried out as follows: 1′-ethylacetyl-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (200 mg, 0.36 mmol) was dissolved in dioxane (9 mL). To the reaction mixture, NaOH (250 μL, 10 N) was added along with 3 mL of water. The reaction mixture was heated at 50° C. for 4 h. The dioxane in the reaction mixture was evaporated and then water was added. HCl (5 N) was slowly added to the mixture to reach pH at 4-5. Reaction mixture was then extracted with CH2CI2 to afford the product as a white solid (197 mg, 95%).

Steps 3-4 in Scheme 3: Conjugation and Deprotection of 1,4,8,11-Tetraazacyclotetradecane-1′-acetyl-[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro phenyl)-4-methyl-1H-pyrazole-3-carboxamide (VYR206)

To a solution of 1′-Acetic acid-[N-(Piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (170 mg, 0.32 mmol) in anhydrous CH2CI2 (25 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (91 mg, 0.48 mmol), hydroxybenzotriazole (HOBt) (65 mg, 0.45 mmol), diethylamine (DEA) (300 μL) and 1,4,8-Tri-Boc-1,4,8,11-tetraazacyclotetradecane (BOC3-cyclam; 163 mg, 0.32 mmol) were added. The mixture was stirred at room temperature for 48 h. The protected BOC3-cyclam-conjugate was isolated by flash column chromatograph using gradient CH2Cl₂/MeOH (100:1 to 100:10) to yield (300 mg, 95%). To de-protect the cyclam conjugate, the BOC3-protected conjugate (175 mg, 0.17 mmol) was dissolved in TFA/CH₂Cl₂ (8 mL; 2:1). The reaction mixture was stirred at room temperature for 6 h. The solvent was then concentrated and the desired product was purified by flash chromatography eluted with CH2CI2/MeOH (100:1 to 100:25) to afford the final compound as a white powder (150 mg, 8 1%). The structure of VYR206 was determined by NMR, MS, and HPLC techniques (FIGS. 9, 10, and 11 respectively).

Example 3

According to the similar N4-strategy approach as described for VYR207 compound in Example 1, two compositions based on natural cannabinoid compounds N4-Cannabidiol (VYC203) and N4-Tetrahydrocannabidiol (VYT205) were synthesized.

VYR203 and VYR205 can be synthesized in several ways. Shown below is a representative scheme, Scheme 4.

Briefly, Tetrahydrocannabinol (THC) (350 mg, 1.11 mmol) was added to a magnetically stirred anhydrous CH3CN (12 mL). The mixture was stirred at room temperature until a solution was obtained (˜10 min). To this solution, bromopropyl-[1,4,8-Tris(trifluoroacetyl)-1,4,8,11-tetraazacyclotetradecane] (bromopropyl-N4-TFA3; bromopropyl-TFA3; 280 mg, 0.3 mmol) and KOH (157 mg, 2.8 mmol) were then added. The mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC (3:1 EtOAc/Hexane). The residue was purified by flash chromatography using Hexane:EtOAc (6:4) as an eluent to afford TFA3-cyclam-THC as a white solid (510 mg, 5 1%). To a solution of TFA3-cyclam-THC conjugate in MeOH (4.0 mL) K2CO3 (420 mg, 7.2 mmol) was added in one portion. Suspension was heated under reflux for 3 h. Toluene (20 mL) was then added to the cooled mixture. MeOH was removed by forming an azeotrope with toluene. After MeOH solvent was completely removed, the hot toluene suspension with inorganic salt was filtered and concentrated to give a desired free base (575 mg, 76%) as a white solid VYT205. The same synthetic route is applied to VYC203 compound.

Example 4

Immunoblot analysis of cell lysates from various DLBCL cell lines was performed to evaluate expression of the CBi receptor (FIG. 12A) with expression of β-actin as the control for sample loading (FIG. 12B), with each cell line identified by respective initials. Western blotting showed very high protein expression levels of CB 1 in the RC cell line in comparison to Tole, TMD, EJ, LP, LY3, and CJ cell lines, while no expression was detectable in FN, HF, DOHH2, and DBR cell lines.

Cell lysates from 24 DLBCL cell lines were analyzed for relative expression of CB land CB₂ mRNAs. In certain cell lines, such as TJ, LY-19, CJ, and BJAB, CBi mRNA was expressed about 10-15% more than CB₂ mRNA. In certain cell lines, such as SF, MZ, Toledo, DBr, SUDHL-4, and MCA, CBi mRNA was expressed about 100-200% more than CB₂ mRNA. In certain cell lines, such as SF, MZ, Toledo, DBr, SUDHL-4, and MCA, CBi mRNA was expressed about 100200% more than CB₂ mRNA; and in cell lines, such as U2392 and EJ, CBi mRNA was expressed about 300-600% more than CB₂ mRNA. In certain cell lines, such as LY-3 and Pheiffer, CB₂ mRNA was expressed about 2-10% more than CBi mRNA. These results show CBi is a viable target in malignant immune cells, along with CB₂ that is known to be primarily associated. Furthermore, CBi may play a pivotal role in lymphoblastic cells, including determination of therapeutic sensitivity or resistance.

Example 5

Cell viability was assessed using MTS assays, a colorimetric method for the sensitive quantification of viable cells based on the reduction of the MTS tetrazolium compound to a colored formazan dye by NAD(P)H-dependent dehydrogenase enzymes in metabolically active cells. The formazan dye is quantified by measuring the absorbance at 490-500 nm. Cell viability assays (MTS) were performed to determine the viability of four DLBCL cancer cell lines—EJ, U2932, CJ and LY19 in vitro (72 h incubation) in the presence of four CB1/CB2 cannabinoid receptor ligands: CBi-selective antagonist CP945,598 (Otenabant), CBi-selective inverse agonists—SR141716 (rimonabant) and AM251, and CB₂-specific agonist AM1241. The effect of cannabinoid receptor ligand SR141716 on the viability of the DLBCL cancer cell lines—EJ, U2932, CJ and LY19 is shown in FIG. 13. The effect of cannabinoid receptor ligand CP945,598 (Otenabant) on the viability of the DLBCL cancer cell lines—EJ, U2932, CJ and LY19 is shown in FIG. 14. The effect of cannabinoid receptor ligand AM 1241 on the viability of the DLBCL cancer cell lines—EJ, U2932, CJ and LY19 is shown in FIG. 15. The effect of cannabinoid receptor ligand AM251 on the viability of the DLBCL cancer cell lines—EJ, U2932, CJ and LY19 is shown in FIG. 16. All compounds depicted in FIGS. 13-16 correspond to non-conjugated (N4 chelator-free) agents. As expected, CB₂ agonist AM 1241 demonstrated a significant effect, however CBi-selective antagonist and inverse agonists (CP945,598, SR141716 and AM251) also had significant results depending on the specific cell line. For example, SR141716 and AM251 appear to have a more potent effect on LY19 where AM251 appears to have the greatest potency for U2932. Overall, the compounds demonstrate that CBi as a target for therapeutic intervention. CB₂ is previously known to be associated with immune cells.

Example 6

In Examples 6-8, N4-conjugated compounds were analyzed. The effects of CBi inverse agonist SR141716 and its conjugated form-VYR206 were analyzed using diffuse large B-cell lymphoma (DLBCL; 16 cancer cell lines; FIGS. 17A and 17B) and mantle cell lymphoma (MCL; 8 cell lines; FIGS. 17C and 17D) cancer cells. Exposure of SR141716 to DLBCL (FIG. 17A) markedly decreased viability than VYR206 (FIG. 17B). Diffuse large B-cell lymphoma cancer cells were resistant to lower VYR206 concentration (<50 μM) (FIG. 17B). The lower-dose of SR141716 (10-40 μM) drug compared to VYR206 indicated the reduction of cell viability (relatively steep initial slopes especially in Rec-1 and SP-53) in MCL cell lines (FIG. 17C). The results showed that exposure of MCL cancer cells to VYR206 (FIG. 17D) led to a substantial decrease in cell viability when compared with the all DLBCL cell lines (FIG. 17B). Exposure to 50 μM VYR206 drug had a significant effect on the induction of cell death (90%) in MCL cell line Jeko and Mino (FIG. 17D). The less effective VYR206 may prove to be beneficial for controlling the dosing. Rimonabant by itself has severe adverse effects in patients with high or chronic dosing. Curtailing or modifying the potency may help to reduce adverse effects while still providing a therapeutic effect against cancerous cells.

Example 7

The effects of SR141716 and VYR206 were analyzed. MTS assays for cell viability (72 h incubation) were performed on diffuse large B-cell lymphoma (DLBCL) cells—LR, MS, RC and DOHH2 (FIGS. 18A-18D) and mantle cell lymphoma (MCL) cells—Jeko, Mino, Rec-1 and JMP1 (FIGS. 19A-19D). Preliminary data shows DLBCL cancer cell lines MS, DOHH2 and mantle cell lymphoma cell line REC-1 are more resistant to drug VYR206 with comparison to other cell lines from FIGS. 18B, 18C, and 19B. The results show that exposure of DLBCL to SR141716 led to induction of cell death (<90%) at drug concentration 50 μM in LR, MS and RC cell lines (FIGS. 18A, 18B, 18D; blue lines) with comparison to DOHH2 cell line, inhibition was >50% SR141716 was more effective to DLBCL than VYR206. Complete DLBCL inhibition with VYR206 was reached at drug concentrations: 200 μM for LR, MS and DOHH2 (FIGS. 18A, 18B, 18C) and 100 μM for RC (FIG. 18D). Mantle cell lymphoma cell lines JEKO, JMP-1 and Mino (FIGS. 19A, 19B, 19D, red lines) were less resistant to VYR206 than DLBCL. It was also observed from FIGS. 18 and 19 that N4 (cyclam) has been proven to have no effect on cell viability in all tested lymphoma cell lines.

Example 8

High throughput screening (THS) assessment of cell viability in 16 DLBCL (FIGS. 20A and 20B) and 8 MCL (FIG. 20C) cell lines were assessed following treatment a 72-hour incubation of the cell lines with cannabidiol, which was obtained as CBD in a coconut oil extract. Cell viability, 90% of the all cells tested, remained viable in a concentration range of 0-5 μM CBD. Complete cell death was obtained at 25 μM CBD concentration only for two cancer cell lines, HT and EJ (FIG. 20B); 50 μM CBD concentration gave a complete cell death viability in seven cell lines MZ, HF, HB, CJ, MS, Toledo and EJ (FIGS. 20A and 20B). Cancer cell line DOHH2 was less susceptible to lower CBD concentration (0-25 μM) (FIG. 20B). After exposure to CBD concentration range 15-20 μM 50% cell viability was reached in 8 cell lines (MZ, HB, CJ, LP, MCA, MT, EJ) (FIGS. 20A and 20B). All screened mantle cell lymphoma cancer cells (Mino, Jeko, SP53, Maver-1Z138, JMP-1, Rec-1 and PF-1) were less sensitive at CBD concentration range from 15 μM to 25 μM (FIG. 20C).

Example 9

⁶⁸Ga-N4-Compound labeling process (Route A of Schemes 5, 6, and 7) was generally initiated by the addition of ⁶⁸Ga chloride (20 mCi in 0.1 N HCl) in vials. The reaction was heated at 70° C. for 15 min and the pH of the product was adjusted to 5-6 with sodium bicarbonate. The tracer product was validated using two analytical tools (reverse phase HPLC and radio-TLC) to determine the active pharmaceutical ingredient (API) purity, API yield, radiochemical purity and yield and specific ⁶⁸Ga-N4-compound activity. In certain compounds, there was a need to use C-18 column to remove unreacted ⁶⁸Ga chloride or ⁶⁸Ga oxide, followed by elution with ethanol. ^(99m)Tc-N4-compound labeling process (Route B of Schemes 5, 6, and 7) was generally initiated by the addition of tin (II) chloride (O.1 g) and ^(99m)Tc pertechnetate (20 mCi in 0.1 mL saline) in vials. The reaction was immediately chelated and the pH of the product was adjusted to 5-6 with saline. The tracer product was validated using two analytical tools (reverse phase HPLC and radio-TLC) to determine the active pharmaceutical ingredient (API) purity, API yield, radiochemical purity and yield and specific ^(99m)Tc-N4-compound activity. Radiochemical purity of ^(99m)Tc-N4-compounds was assessed by high-performance liquid chromatography (HPLC), equipped with Nal and UV detector (274 nm), and was performed using a C-18 reverse column with a mobile phase of acetonitrile:water (7:3) at a flow rate of 0.5 mL/min.

Radiochemical purity was also determined by radio-TLC (ITLC SG, Gelman Sciences, Ann Arbor, Mich.) eluted with ammonium acetate (1M in water): methanol (6:1). High-performance liquid chromatography (HPLC), equipped with a Nal detector and UV detector (254 nm), was performed on a gel permeation column (Biosep SEC-S3000, 7.8 300 mm, Phenomenex, Torrance, Calif.) using a flow rate of 1.0 mL/min. The eluant was 0.1% LiBr in phosphate buffered saline (PBS) (10 mM, pH 7.4).

Example 11

The effect of different amounts of combinations of VYR206 and CBD on various DLBCL and MCL cell lines were evaluated by immunoblot analysis. Immunoblot analysis of cell lysates from various DLBCL and MCL cell lines was performed to show effects on expression of CBi and CB₂ receptors with the expression of β-actin as the control for sample loading (FIGS. 21A-21D), with each cell line identified by respective initials. Northern blotting showed decreasing RNA expression levels of CBi with increased amounts of conjugated CBi inverse agonist VYR206 with predominately no change in CB₂ expression. Moreover, FIGS. 21B and 21C shows a modulation in CB₂ mRNA expression levels with VYR206 and CBD administration.

Example 12

Cell viability assays (MTS) were performed to determine the viability of MCL (Mino, Jeko, Sp-53, Mayer, Z-138, JMP-1, Rec-1 and PF-1) and DLBCL (CJ, LP, RC, TMD-8, WP, LY-3, LY-19 and MZ) cancer cell lines in vitro (72 h incubation) in the presence of a cannabinoid receptor ligand, cannabidiol CBD-99, which is a hemp derived cannabidiol from Isodiol International Inc., headquartered in Vancouver, Canada, and has 99% purity. The efficacy of the cannabidiol CBD-99 on the viability of various MCL and DLBCL cell lines is shown in FIGS. 22A and 22B, respectively. The cannabidiol compound CBD-99 used in Example 12 is a non-conjugated (N4 chelator-free) agent.

Example 13

Cell viability assays (MTS) were performed to determine the viability of DLBCL and MCL cancer cell lines in vitro (72 h incubation) in the presence of CB i-selective inverse agonists—rimonabant (identified as Rimo) and Bruton's tyrosine kinase inhibitor-Ibrutinib (identified as IBN). The IC50 values of rimonabant and Ibrutinib on the viability of various DLBCL cell lines are shown in FIG. 23, and of various MCL cell lines (Jeko, Mino, PF-4 and PF-5) are shown in FIGS. 24A-24D. All compounds depicted in FIGS. 23 and 24A-24D correspond to non-conjugated (N4 chelator-free) agents. FIGS. 24A-24D are graphical representations of the effect of the rimonabant and ibrutinib on the viability of MCL cell lines (Jeko, Jeko-R, Mino, Mino-R, PF-4 and PF-5) cell lines' viability. FIG. 24A is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on Jeko and Jeko-R cell lines. FIG. 24B is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on Mino and Mino-R. FIG. 24C is a graphical representation of efficacy of ibrutinib on PF-4 and PF-5 cell lines. FIG. 24D is a graphical representation of the effect of 25 μM of rimonabant and ibrutinib on PF-4 and PF-5.

TABLE 5 rimonabant ibrutinib EJ 20.61 30 CJ 13.51 25 LY19 15.19 10 HF 32.68 18 McA 21.79 20 MS 23.67 20 LY-10 25.06 0.5 Ly-3 25.22 20 LP 27.1 6 LR 30.89 20 HB 29.44 20 WP 25.49 1 U2932 26.15 15 Average 24.367 15.80 IC₅₀

Example 14

Cell viability assays (MTS) were also performed to determine the viability of DLBCL and MCL cancer cell lines in vitro (72 h incubation) in the presence of conjugated CBi-selective inverse agonists—VYR206. IC50 values on DLBCL cell line's viability is shown in Table 6.

TABLE 6 BYR206 Cell line IC₅₀ (μM) SUDHL-4 63 HF 74 McA 6 MZ 138 FN 69 CJ 100 MS 63 DS 57 Toledo 29 Pfeiffer 25 LY19 8 BJAB 58 RC 5 DB 8 HT 45 SUDHL-10 155 LR 8 LY10 7 LY3 6 U2932 88 LP 13 HBL-1 101

Example 15

The efficacy of rimonabant and its cyclam conjugated form, VYR206 on the viability of DLCBL cell lines (LR, MS, RC and DOHH2) and MCL cell lines (Jeko, Rec-1, Mino and JMP-1) was evaluated with cyclam as the control. FIGS. 25A-25H are graphical representations of the efficacy of rimonabant and its cyclam conjugated form, VYR206 on the viability of DLCBL cell lines (LR, MS, RC and DOHH2) and MCL cell lines (Jeko, Rec-1, Mino and JMP-1). FIG. 25A is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of LR cell line with cyclam as a control. FIG. 25B is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of MS cell line with cyclam as a control. FIG. 25C is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of RC cell line with cyclam as a control. FIG. 25D is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of DOHH2 cell line with cyclam as a control. FIG. 25E is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Jeko cell line with cyclam as a control. FIG. 25F is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Rec-1 cell line with cyclam as a control. FIG. 25G is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of Mino cell line with cyclam as a control. FIG. 2511 is a graphical representation of the efficacy of rimonabant and VYR206 on the viability of JMP-1 cell line with cyclam as a control. VYR206 follows the same dose response pattern as the unconjugated rimonabant but with decreased potency. This decreased potency can help decrease the toxicity and other side effects associated with rimonabant. Most of the cell lines presented have some sensitivity to VYR206 where Rec-1 appears to be resistant. This may prove that VYR206 may be selective to certain cell lines.

Example 16

Cell viability assays (MTS) were performed to determine the viability of DLBCL (RC) and MCL (Mino) cancer cell lines in vitro (72 hour-incubation) in the presence of CB₂-agonist—CBD alone and in combination with ibrutinib. Results are shown in FIG. 26A. Cell viability assays (MTS) were performed to determine the viability of DLBCL (RC) and MCL (Mino) cancer cell lines in vitro (72 h incubation) in the presence of CBD alone and in combination with zanubrutinib (BGB). Results are shown in FIG. 26B. Cell viability assays (MTS) were performed to determine the viability of DLBCL (RC) and MCL (Mino) cancer cell lines in vitro (72 h incubation) in the presence of CBD alone and in combination with carfilzomib (CFZ). Results are shown in FIG. 26C. Cell viability assays (MTS) were performed to determine the viability of DLBCL (RC) and MCL (Mino) cancer cell lines in vitro (72 h incubation) in the presence CBD alone and in combination with tumorex (TMX). Results are shown in FIG. 26D. Comparative reduction in viability with CBD versus chemotherapeutic agents were demonstrated in FIGS. 26A-26D where each combination demonstrates a marked reduction in both cell lines, for what appears to be synergistic effect. At the given amounts of CBD and the chosen chemotherapeutic s individually, there was modest reduction in viability, but the combination in each instance caused a synergistic effect on MCL (Mino) and DLBCL (RC) cell lines. This demonstrates combinations of the cannabinoid ligands with chemotherapeutic s can enhance therapeutic effects of the chemotherapeutic compound.

Example 17

To determine whether cyclam-conjugated CB₂ agonist CBD and cyclam-conjugated CBi inverse agonist VYR206 at various concentrations resulted in induction of apoptosis, RC cells were treated with increasing concentration of cyclam-conjugated conjugated CBD or VYR206 for 24 hrs. No activation of apoptosis in untreated cells was observed (control not shown). Concentration-dependent increase was detected in cleaved PARP after treatment with cyclam-conjugated conjugated CBD and VYR206. At 12.5 μM CBD and 50 μM VYR206, there was significant apoptosis induction in cleaved PARP expression. Immunoblot analysis showing the induction of apoptosis through the effects on expression of cPARP are shown in FIG. 27A with expression of β-actin as the control for sample loading in FIG. 27B for cells treated with cyclam-conjugated CB₂ agonist CBD and cyclam-conjugated CBi inverse agonist VYR206 at 6.25, 12.5, 25, and 50 μM. Western blotting showed increasing protein expression levels of cPARP with increased amounts of cyclam-conjugated conjugated CBD and VYR206.

To determine whether different CBD concentrations resulted in induction of apoptosis, BJAB cells were treated with increasing concentration of CBD for 24 hrs. No activation of apoptosis in untreated cells (control not shown). It was observed a concentration-dependent increase in cleaved caspases 3 and cleaved PARP after CBD treatment. At 12.5 μM CBD, there was significant apoptosis induction in cleaved PARP expression. The effect of CBD on both cleaved caspase 3 (FIG. 27C) and cleaved PARP expression (FIG. 27D) was analyzed using Western analysis. Expression of the β-actin (FIG. 27E) was used as a control for equal loading.

Example 18

Cell viability assays (MTS) were performed to determine the viability of DLBCL (LY19 and LR) cancer cell lines in vitro (72 h incubation) in the presence of CB₂— agonist—CBD in comparison and in combination with conjugated CBi inverse agonist-VYR206. Results are shown in FIGS. 28A and 28B. CBD has mixed affinity for both CBi and CB₂ receptors and had demonstrated generally the same response as VYR206 alone and in combination.

Example 19

Genetic profile analysis of DLBCL (RC) cell line for probing for potential molecular marker to develop a target based molecular signature. The expression of genes in untreated and rimonabant treated cells showing the range of under expression (green) to over expression (red) shown in FIG. 29. Genes with significant change in expression in untreated versus treated cells and their functional association are further listed in Table 7.

TABLE 7 Function Gene DNA Damage Histone H3, DH-Histone H3, H2AX, DM-K9-Histone H3, PMS2 RPA32 Apoptosis Caspase 3, cleaved caspase 7, Bad, bak, Smac Cell cycle Chk1, Chk2, Aurora B, p27-kip-1, cyclin D1, Rb, ATM, cyclin B1 Metabolic Glutamate, HIF-1a, SLC1A5, LDHA, TIGAR, TFAM Growth/Survival AKT, PI3K, Src, b-catenin, STAT3, Rictor, S6, NDRG1, Prex-1, SMAD3, c-Met, Lck Ubiqutin/proteasome UBAC1, BAP1 Autophagy LC3A

Proteomic profile analysis of DLBCL (RC) cell line to demonstrate correlation between most significant proteins is shown in Table 7. These proteins regulate various cellular function ranging from cell adhesion to cell growth and proliferation to apoptosis. For example, Fox03a, known to be associated with the trigger of apoptosis, is shown to have a positive linear relationship with N-Cadherin and RPA32 which are associated with cell adhesion and replication respectively. These correlations provide further insight to potentially understanding the mechanism of cell signaling that is occurring in the DLBCL cell line (RC) and where the cannabinoid receptor activation may be involved.

TABLE 7 r value p value Pearson Notch1 vs RPA32 −0.5939 0.0036 N-Cadherin vs Rictor −0.4318 0.0448 N-Cadherin vs RPA32 0.476 0.0251 N-Cadherin vs FoxO3a 0.7755 0.0001 RPA32 vs FoxO3a 0.5947 0.0035 Spearman Notch1 vs elF4G −0.4376 0.0417 Notch1 vs RPA32 −0.5088 0.0156 N-Cadherin vs Rictor −0.5336 0.0105 N-cadherin vs RPA32 0.5471 0.0084 N-Cadherin vs FoxO3a 0.6375 0.0014 RPA32 vs FoxO3a 0.6126 0.0024

This application is a continuation of U.S. patent application Ser. No. 16/291,943, filed Mar. 4, 2019, title “Systems and Methods for Integrated and Comprehensive Management of Cannabis Products,” which is a continuation-in-part application of U.S. patent application Ser. No. 15/470,562, filed on Mar. 27, 2017, titled “Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes,” which is a continuation application of U.S. patent application Ser. No. 14/312,051, filed on Jun. 23, 2014, now issued as U.S. Pat. No. 9,632,069, titled “Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes,” which claims the benefit of and priority to U.S. Provisional Patent Application No. 61/936,200, filed on Feb. 5, 2014, titled “Systems and Methods of Evaluating Cannabis Products for Public Safety, Quality Control and Quality Assurance Purposes”; and U.S. Provisional Patent Application No. 61/939,385, filed on Feb. 13, 2014, titled “Systems and Methods of Evaluating Cannabis Products for Public Safety, Quality Control and Quality Assurance Purposes,” the disclosures of which are each hereby incorporated by reference in their entireties. This application is also a continuation-in-part application under 35 U.S.C. § 111(a) of the PCT application No. PCT/US2018/42707, filed on Jul. 18, 2018, titled “Compositions Containing Cannabinoid Analog Conjugates and Methods of Use,” which claims the benefit of and priority to U.S. Provisional Patent Application No. 62/533,894, filed on Jul. 18, 2017, titled “Compositions Containing Cannabinoid Analog Conjugates and Methods of Use,” the disclosures of which are each hereby incorporated by reference in their entireties.

Moreover, the foregoing has broadly outlined certain objectives, features, and technical advantages of the present disclosure and a detailed description of the disclosure so that embodiments of the disclosure may be better understood in light of features and advantages of the disclosure as described herein, which form the subject of certain claims of the disclosure. It should be appreciated that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present disclosure. It should also be realized that such equivalent constructions do not depart from the disclosure as set forth in the appended claims. The novel features that are believed to be characteristic of the disclosure, both as to its organization and method of operation, together with further objects and advantages is better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that such description and figures are provided for the purpose of illustration and description only and are not intended as a definition of the limits of the present disclosure. It will be apparent to those skilled in the art that various modifications and changes can be made within the spirit and scope of the disclosure as described in the foregoing specification.

Further modifications and alternative embodiments of various aspects of the compositions and methods disclosed here will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the embodiments. It is to be understood that the forms of the embodiments shown and described here are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described here, parts and processes may be reversed or omitted, and certain features of the embodiments may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the embodiments. Changes may be made in the elements described here without departing from the spirit and scope of the embodiments as described in the following claims.

The foregoing descriptions of methods, compositions, and results obtained using them are provided merely as illustrative examples. Descriptions of the methods are not intended to require or imply that the steps of the various embodiments must be performed in the order presented. As will be appreciated by one of ordinary skill in the art, the steps in the foregoing embodiments may be performed in any order. Words such as “then” are not intended to limit the order of the steps; these words are simply used to guide the reader through the description of the methods. Many of the operations may be performed in parallel or concurrently. In addition, the order of the operations may be rearranged. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined here may be applied to other embodiments without departing from the spirit or scope of the disclosure. 

1. A composition comprising a conjugate of a label, a chelator, and a cannabinoid analog.
 2. The composition of claim 1, wherein the label is a radionuclide.
 3. The composition of claim 1, wherein the label is one or more of Technetium-99, Gallium-68, Copper-60, Copper-64, Indium-Ill, Holmium-166, Rhenium-186, Rhenium-188, Yttrium-90, Lutetium-177, Radium-223, or Actinium-225.
 4. The composition claim 1, wherein the label is configured to facilitate contrast-enhanced imaging, when the composition is administered to a mammal during use.
 5. The composition of claim 1, wherein the cannabinoid analog is an immune check point cannabinoid receptor ligand.
 6. The composition of claim 1, wherein the cannabinoid analog is a synthetic cannabinoid receptor agonist.
 7. The composition as in any one of the preceding claims, wherein the cannabinoid analog is a natural cannabinoid receptor agonist.
 8. The composition of claim 1, wherein the cannabinoid analog is an aminoalkylindole.
 9. The composition of claim 1, wherein the cannabinoid analog is a cannabinoid receptor inverse agonist.
 10. The composition of claim 1, wherein the cannabinoid analog belongs to the group consisting of anandamide (AEA), 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine, and N-arachidonylodopamine (NADA).
 11. The composition of claim 1, wherein the cannabinoid analog is a diarylopyrazole.
 12. The composition of claim 1, wherein the chelator is an aminated or an acid chelator.
 13. The composition of claim 1, wherein the chelator is a cyclam.
 14. The composition of claim 1, wherein the cannabinoid analog is cyclam-1′-acetyl [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide.
 15. The composition of claim 1, wherein the cannabinoid analog is cyclam-1′-propyl [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide.
 16. A method for diagnosing a medical condition in a human subject, the method comprising administering to a human subject an effective amount of the composition of claim
 1. 17. A method of imaging a plurality of cancer cells, the method comprising: administering to a human patient an effective amount of the composition of claim
 1. 18. A method for treating a cancer amenable to treatment with a cannabinoid, the method comprising: administering to a human subject in need thereof an effective amount of the composition of claim
 1. 19. A method for treating a neurologic disorder amenable to treatment with a cannabinoid, the method comprising: administering to a human subject in need thereof an effective amount of the composition of claim
 1. 20. A method for alleviating pain in a human subject, the method comprising: administering to a human subject in need thereof an effective amount of the composition of claim
 1. 21. A kit for imaging cells, comprising: a predetermined quantity of a conjugate of a chelator and a medical cannabinoid analog; and a predetermined quantity of an imaging agent.
 22. The kit of claim 21, further comprising a tin-containing reducing agent. 